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Total registered 109,281 108,046 100.0 117,134 115,752 100.0 122,127 120,631 100.0 122,529 120,970 100.0
Ineligible Records Patients % Records Patients % Records Patients % Records Patients %
Incomplete data 61 61 <0.1 37 37 <0.1 33 33 <0.1 12 12 <0.1
Not resident in England or Wales 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
In situ neoplasm 391 356 0.3 553 497 0.4 712 649 0.5 1,082 1,016 0.8
Benign or uncertain 3,125 2,477 2.3 3,898 3,160 2.7 4,706 3,902 3.2 4,274 3,429 2.8
Metastatic 50 50 <0.1 49 49 <0.1 62 62 <0.1 62 62 <0.1
Otherwise ineligible 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Lymphoma 23 22 <0.1 32 32 <0.1 25 25 <0.1 19 19 <0.1
Leukaemia or myeloma 7 7 <0.1 0 0 0.0 0 0 0.0 0 0 0.0
Total ineligible 2,973 2.8 3,775 3.3 4,671 3.9 4,538 3.8
Total eligible 105,073 100.0 111,977 100.0 115,960 100.0 116,432 100.0
Aged 100+ 28 28 <0.1 38 38 <0.1 39 39 <0.1 39 39 <0.1
Vital status unknown 182 124 0.1 156 121 0.1 208 176 0.2 149 139 0.1
Sex not known 1 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Sex-site error 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Invalid dates 8 7 <0.1 9 8 <0.1 22 21 <0.1 37 35 <0.1
Death certificate only 3,797 3,772 3.6 3,727 3,692 3.3 2,986 2,960 2.6 2,220 2,209 1.9
Autopsy only 161 155 0.1 134 131 0.1 121 119 0.1 94 91 <0.1
Synchronous tumours 595 296 0.3 683 337 0.3 1,051 767 0.7 692 413 0.4
Multiple primary same site 544 142 0.1 837 365 0.3 967 473 0.4 1,087 573 0.5
Total exclusions 4,524 4.3 4,692 4.2 4,555 3.9 3,499 3.0
Patients available for analyses 100,549 95.7 107,285 95.8 111,405 96.1 112,933 97.0
Total registered 126,967 125,035 100.0 133,227 131,144 100.0 68,301 67,483 100.0 799,566 789,061 100.0
Ineligible Records Patients % Records Patients % Records Patients % Records Patients %
Incomplete data 16 16 <0.1 10 10 <0.1 20 20 <0.1 189 189 <0.1
Not resident in England or Wales 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
In situ neoplasm 1,443 1,350 1.1 2,130 1,995 1.5 1,374 1,308 1.9 7,685 7,171 0.9
Benign or uncertain 4,566 3,511 2.8 4,919 3,803 2.9 2,199 1,896 2.8 27,687 22,178 2.8
Metastatic 26 26 <0.1 20 20 <0.1 3 3 <0.1 272 272 <0.1
Otherwise ineligible 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Lymphoma 25 23 <0.1 20 20 <0.1 4 4 <0.1 148 145 <0.1
Leukaemia or myeloma 1 1 <0.1 1 1 <0.1 0 0 0.0 9 9 <0.1
Total ineligible 4,927 3.9 5,849 4.5 3,231 4.8 29,964 3.8
Total eligible 120,108 100.0 125,295 100.0 64,252 100.0 759,097 100.0
Aged 100+ 34 33 <0.1 40 39 <0.1 27 26 <0.1 245 242 <0.1
Vital status unknown 142 125 0.1 120 110 <0.1 60 40 <0.1 1,017 835 0.1
Sex not known 1 0 0.0 3 0 0.0 0 0 0.0 5 0 0.0
Sex-site error 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Invalid dates 38 36 <0.1 17 16 <0.1 198 194 0.3 329 317 <0.1
Death certificate only 2,284 2,265 1.9 2,288 2,264 1.8 1,114 1,107 1.7 18,416 18,269 2.4
Autopsy only 74 73 <0.1 63 63 <0.1 41 41 <0.1 688 673 <0.1
Synchronous tumours 732 411 0.3 806 461 0.4 425 243 0.4 4,984 2,928 0.4
Multiple primary same site 1,412 790 0.7 1,576 907 0.7 950 578 0.9 7,373 3,828 0.5
Total exclusions 3,733 3.1 3,860 3.1 2,229 3.5 27,092 3.6
Patients available for analyses 116,375 96.9 121,435 96.9 62,023 96.5 732,005 96.4
2003-04 2005-06 2007 1995-2007
Table 1: Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis 
(1995-2007), all 12 jurisdictions combined: colorectal cancer
1995-96 1997-98 1999-2000 2001-02
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Total registered 114,804 114,702 100.0 114,920 114,816 100.0 116,189 116,064 100.0 115,622 115,497 100.0
Ineligible Records Patients % Records Patients % Records Patients % Records Patients %
Incomplete data 71 71 <0.1 47 47 <0.1 28 28 <0.1 33 33 <0.1
Not resident in England or Wales 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
In situ neoplasm 20 17 <0.1 21 20 <0.1 23 21 <0.1 16 13 <0.1
Benign or uncertain 1,041 1,019 0.9 967 941 0.8 798 781 0.7 461 452 0.4
Metastatic 386 386 0.3 229 229 0.2 295 295 0.3 275 274 0.2
Otherwise ineligible 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Lymphoma 21 21 <0.1 14 14 <0.1 18 18 <0.1 17 17 <0.1
Leukaemia or myeloma 7 7 <0.1 1 1 <0.1 1 1 <0.1 5 5 <0.1
Total ineligible 1,521 1.3 1,252 1.1 1,144 1.0 794 0.7
Total eligible 113,181 100.0 113,564 100.0 114,920 100.0 114,703 100.0
Aged 100+ 6 6 <0.1 8 8 <0.1 11 11 <0.1 12 11 <0.1
Vital status unknown 152 82 <0.1 144 97 <0.1 205 178 0.2 138 106 <0.1
Sex not known 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Sex-site error 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Invalid dates 18 14 <0.1 37 33 <0.1 14 13 <0.1 7 6 <0.1
Death certificate only 7,626 7,585 6.7 7,108 7,088 6.2 6,080 6,065 5.3 4,671 4,659 4.1
Autopsy only 391 386 0.3 328 320 0.3 248 246 0.2 243 240 0.2
Synchronous tumours 259 238 0.2 260 236 0.2 491 445 0.4 263 206 0.2
Multiple primary same site 63 12 <0.1 100 41 <0.1 162 88 <0.1 196 116 0.1
Total exclusions 8,323 7.4 7,823 6.9 7,046 6.1 5,344 4.7
Patients available for analyses
104,858 92.6 105,741 93.1 107,874 93.9 109,359 95.3
Total registered 118,510 118,367 100.0 123,098 122,925 100.0 62,327 62,236 100.0 765,470 764,607 100.0
Ineligible Records Patients % Records Patients % Records Patients % Records Patients %
Incomplete data 9 9 <0.1 14 14 <0.1 7 7 <0.1 209 209 <0.1
Not resident in England or Wales 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
In situ neoplasm 20 20 <0.1 16 16 <0.1 7 6 <0.1 123 113 <0.1
Benign or uncertain 366 345 0.3 289 269 0.2 153 147 0.2 4,075 3,954 0.5
Metastatic 104 104 <0.1 96 93 <0.1 28 28 <0.1 1,413 1,409 0.2
Otherwise ineligible 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Lymphoma 18 17 <0.1 19 18 <0.1 9 8 <0.1 116 113 <0.1
Leukaemia or myeloma 1 1 <0.1 1 1 <0.1 1 1 <0.1 17 17 <0.1
Total ineligible 496 0.4 411 0.3 197 0.3 5,815 0.8
Total eligible 117,871 100.0 122,514 100.0 62,039 100.0 758,792 100.0
Aged 100+ 14 14 <0.1 25 25 <0.1 7 5 <0.1 83 80 <0.1
Vital status unknown 102 94 <0.1 86 72 <0.1 23 16 <0.1 850 645 <0.1
Sex not known 0 0 0.0 1 0 0.0 0 0 0.0 1 0 0.0
Sex-site error 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Invalid dates 15 14 <0.1 13 8 <0.1 31 28 <0.1 135 116 <0.1
Death certificate only 5,280 5,264 4.5 5,091 5,063 4.1 2,844 2,837 4.6 38,700 38,561 5.1
Autopsy only 146 145 0.1 167 166 0.1 113 113 0.2 1,636 1,616 0.2
Synchronous tumours 234 190 0.2 281 221 0.2 147 108 0.2 1,935 1,644 0.2
Multiple primary same site 262 164 0.1 343 225 0.2 218 154 0.2 1,344 800 0.1
Total exclusions 5,885 5.0 5,780 4.7 3,261 5.3 43,462 5.7
Patients available for analyses
111,986 95.0 116,734 95.3 58,778 94.7 715,330 94.3
2003-04 2005-06 2007 1995-2007
Table 2: Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis 
(1995-2007), all 12 jurisdictions combined: lung cancer
1995-96 1997-98 1999-2000 2001-02
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Total registered 122,919 122,393 100.0 132,491 131,604 100.0 139,188 138,172 100.0 143,751 142,614 100.0
Ineligible Records Patients % Records Patients % Records Patients % Records Patients %
Incomplete data 105 105 <0.1 69 68 <0.1 37 36 <0.1 14 14 <0.1
Not resident in England or Wales 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
In situ neoplasm 5,218 5,027 4.1 6,547 6,307 4.8 7,604 7,349 5.3 8,458 8,188 5.7
Benign or uncertain 358 342 0.3 405 389 0.3 297 280 0.2 313 279 0.2
Metastatic 21 21 <0.1 21 20 <0.1 30 30 <0.1 21 21 <0.1
Otherwise ineligible 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Lymphoma 15 15 <0.1 17 17 <0.1 18 18 <0.1 13 13 <0.1
Leukaemia or myeloma 1 1 <0.1 0 0 0.0 0 0 0.0 0 0 0.0
Total ineligible 5,511 4.5 6,801 5.2 7,713 5.6 8,515 6.0
Total eligible 116,882 100.0 124,803 100.0 130,459 100.0 134,099 100.0
Aged 100+ 65 65 <0.1 56 56 <0.1 82 82 <0.1 77 76 <0.1
Vital status unknown 285 190 0.2 262 201 0.2 303 266 0.2 300 283 0.2
Sex not known 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Sex-site error 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Invalid dates 4 4 <0.1 9 7 <0.1 6 6 <0.1 35 34 <0.1
Death certificate only 2,673 2,627 2.2 2,863 2,817 2.3 2,299 2,256 1.7 1,716 1,684 1.3
Autopsy only 20 20 <0.1 20 19 <0.1 15 15 <0.1 9 9 <0.1
Synchronous tumours 673 539 0.5 920 577 0.5 1,489 1,057 0.8 1,140 697 0.5
Multiple primary same site 324 55 <0.1 878 414 0.3 1,358 834 0.6 1,761 1,153 0.9
Total exclusions 3,500 3.0 4,091 3.3 4,516 3.5 3,936 2.9
Patients available for analyses
113,382 97.0 120,712 96.7 125,943 96.5 130,163 97.1
Total registered 150,970 149,318 100.0 156,212 154,153 100.0 78,762 77,925 100.0 924,293 916,179 100.0
Ineligible Records Patients % Records Patients % Records Patients % Records Patients %
Incomplete data 17 17 <0.1 14 14 <0.1 5 5 <0.1 261 259 <0.1
Not resident in England or Wales 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
In situ neoplasm 9,866 9,337 6.3 11,532 10,768 7.0 5,988 5,729 7.4 55,213 52,705 5.8
Benign or uncertain 301 261 0.2 349 311 0.2 202 187 0.2 2,225 2,049 0.2
Metastatic 10 10 <0.1 9 9 <0.1 2 1 <0.1 114 112 <0.1
Otherwise ineligible 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Lymphoma 12 11 <0.1 6 6 <0.1 3 2 <0.1 84 82 <0.1
Leukaemia or myeloma 0 0 0.0 0 0 0.0 0 0 0.0 1 1 <0.1
Total ineligible 9,636 6.5 11,108 7.2 5,924 7.6 55,208 6.0
Total eligible 139,682 100.0 143,045 100.0 72,001 100.0 860,971 100.0
Aged 100+ 77 77 <0.1 92 91 <0.1 39 39 <0.1 488 486 <0.1
Vital status unknown 265 247 0.2 313 303 0.2 81 76 0.1 1,809 1,566 0.2
Sex not known 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Sex-site error 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Invalid dates 62 58 <0.1 20 18 <0.1 23 22 <0.1 159 149 <0.1
Death certificate only 1,523 1,485 1.1 1,188 1,151 0.8 591 572 0.8 12,853 12,592 1.5
Autopsy only 10 10 <0.1 11 11 <0.1 6 6 <0.1 91 90 <0.1
Synchronous tumours 1,493 932 0.7 1,544 860 0.6 724 412 0.6 7,983 5,074 0.6
Multiple primary same site 2,488 1,660 1.2 3,201 2,278 1.6 1,682 1,270 1.8 11,692 7,664 0.9
Total exclusions 4,469 3.2 4,712 3.3 2,397 3.3 27,621 3.2
Patients available for analyses
135,213 96.8 138,333 96.7 69,604 96.7 833,350 96.8
2003-04 2005-06 2007 1995-2007
Table 3: Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis 
(1995-2007), all 12 jurisdictions combined: breast cancer (women)
1995-96 1997-98 1999-2000 2001-02
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Total registered 20,194 20,134 100.0 21,193 21,150 100.0 21,172 21,124 100.0 21,778 21,713 100.0
Ineligible Records Patients % Records Patients % Records Patients % Records Patients %
Incomplete data 30 30 0.1 8 8 <0.1 5 5 <0.1 25 25 0.1
Not resident in England or Wales 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
In situ neoplasm 197 195 1.0 80 79 0.4 29 28 0.1 35 35 0.2
Benign or uncertain 1,586 1,562 7.8 1,729 1,713 8.1 1,658 1,633 7.7 1,626 1,569 7.2
Metastatic 110 110 0.5 48 48 0.2 91 91 0.4 60 60 0.3
Otherwise ineligible 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Lymphoma 1 1 <0.1 2 2 <0.1 0 0 0.0 0 0 0.0
Leukaemia or myeloma 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Total ineligible 1,898 9.4 1,850 8.7 1,757 8.3 1,689 7.8
Total eligible 18,236 100.0 19,300 100.0 19,367 100.0 20,024 100.0
Aged 100+ 4 4 <0.1 0 0 0.0 7 7 <0.1 5 5 <0.1
Vital status unknown 45 18 <0.1 29 21 0.1 33 28 0.1 32 28 0.1
Sex not known 0 0 0.0 1 1 <0.1 0 0 0.0 0 0 0.0
Sex-site error 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Invalid dates 3 2 <0.1 3 3 <0.1 0 0 0.0 3 3 <0.1
Death certificate only 790 784 4.3 797 790 4.1 770 764 3.9 592 588 2.9
Autopsy only 29 29 0.2 16 16 <0.1 13 13 <0.1 12 12 <0.1
Synchronous tumours 45 23 0.1 40 25 0.1 59 45 0.2 48 29 0.1
Multiple primary same site 34 9 <0.1 34 16 <0.1 28 12 <0.1 35 15 <0.1
Total exclusions 869 4.8 872 4.5 869 4.5 680 3.4
Patients available for analyses
17,367 95.2 18,428 95.5 18,498 95.5 19,344 96.6
Total registered 21,245 21,203 100.0 21,295 21,250 100.0 10,648 10,625 100.0 137,525 137,199 100.0
Ineligible Records Patients % Records Patients % Records Patients % Records Patients %
Incomplete data 9 9 <0.1 24 24 0.1 3 3 <0.1 104 104 <0.1
Not resident in England or Wales 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
In situ neoplasm 28 25 0.1 29 26 0.1 46 46 0.4 444 434 0.3
Benign or uncertain 1,529 1,501 7.1 1,593 1,577 7.4 868 854 8.0 10,589 10,409 7.6
Metastatic 29 29 0.1 19 19 <0.1 6 6 <0.1 363 363 0.3
Otherwise ineligible 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Lymphoma 4 4 <0.1 1 1 <0.1 0 0 0.0 8 8 <0.1
Leukaemia or myeloma 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Total ineligible 1,568 7.4 1,647 7.8 909 8.6 11,318 8.2
Total eligible 19,635 100.0 19,603 100.0 9,716 100.0 125,881 100.0
Aged 100+ 8 8 <0.1 5 5 <0.1 5 5 <0.1 34 34 <0.1
Vital status unknown 26 26 0.1 54 32 0.2 11 9 <0.1 230 162 0.1
Sex not known 0 0 0.0 0 0 0.0 0 0 0.0 1 1 <0.1
Sex-site error 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Invalid dates 3 3 <0.1 2 2 <0.1 9 8 <0.1 23 21 <0.1
Death certificate only 523 519 2.6 474 470 2.4 268 266 2.7 4,214 4,181 3.3
Autopsy only 11 11 <0.1 18 18 <0.1 5 5 <0.1 104 104 <0.1
Synchronous tumours 53 37 0.2 50 34 0.2 20 14 0.1 315 207 0.2
Multiple primary same site 41 28 0.1 36 21 0.1 19 11 0.1 227 112 <0.1
Total exclusions 632 3.2 582 3.0 318 3.3 4,822 3.8
Patients available for analyses
19,003 96.8 19,021 97.0 9,398 96.7 121,059 96.2
2003-04 2005-06 2007 1995-2007
Table 4: Ineligible and excluded records, and no. (%) of eligible patients included in analyses, by calendar period of diagnosis 
(1995-2007), all 12 jurisdictions (except Swedish regions) combined: ovarian cancer
1995-96 1997-98 1999-2000 2001-02




















Australian registries 15-44 597 517 611 532 1,208 1,049 379 348 385 345 764 693 662 484 716 530 1,378 1,014
45-54 1,720 1,469 1,349 1,155 3,069 2,624 1,118 980 904 793 2,022 1,773 1,774 1,306 1,547 1,131 3,321 2,437
55-64 3,982 3,275 2,568 2,151 6,550 5,426 2,529 2,188 1,728 1,500 4,257 3,688 4,551 3,345 3,011 2,160 7,562 5,505
65-74 6,346 4,932 4,415 3,560 10,761 8,492 3,953 3,249 2,709 2,191 6,662 5,440 6,592 4,624 4,452 3,112 11,044 7,736
75-99 5,202 3,460 5,831 3,875 11,033 7,335 3,922 2,671 4,038 2,739 7,960 5,410 6,896 4,340 7,000 4,488 13,896 8,828
Total 17,847 13,653 14,774 11,273 32,621 24,926 11,901 9,436 9,764 7,568 21,665 17,004 20,475 14,099 16,726 11,421 37,201 25,520
New South Wales 15-44 322 280 330 290 652 570 217 202 188 170 405 372 371 264 378 272 749 536
45-54 1,022 868 779 653 1,801 1,521 603 528 516 457 1,119 985 1,027 751 850 626 1,877 1,377
55-64 2,298 1,898 1,517 1,265 3,815 3,163 1,501 1,314 1,045 919 2,546 2,233 2,633 1,913 1,778 1,257 4,411 3,170
65-74 3,561 2,799 2,416 1,960 5,977 4,759 2,209 1,826 1,520 1,232 3,729 3,058 3,773 2,636 2,536 1,776 6,309 4,412
75-99 2,906 1,940 3,207 2,141 6,113 4,081 2,099 1,453 2,177 1,465 4,276 2,918 3,804 2,368 3,961 2,561 7,765 4,929
Total 10,109 7,785 8,249 6,309 18,358 14,094 6,629 5,323 5,446 4,243 12,075 9,566 11,608 7,932 9,503 6,492 21,111 14,424
Victoria 15-44 275 237 281 242 556 479 162 146 197 175 359 321 291 220 338 258 629 478
45-54 698 601 570 502 1,268 1,103 515 452 388 336 903 788 747 555 697 505 1,444 1,060
55-64 1,684 1,377 1,051 886 2,735 2,263 1,028 874 683 581 1,711 1,455 1,918 1,432 1,233 903 3,151 2,335
65-74 2,785 2,133 1,999 1,600 4,784 3,733 1,744 1,423 1,189 959 2,933 2,382 2,819 1,988 1,916 1,336 4,735 3,324
75-99 2,296 1,520 2,624 1,734 4,920 3,254 1,823 1,218 1,861 1,274 3,684 2,492 3,092 1,972 3,039 1,927 6,131 3,899
Total 7,738 5,868 6,525 4,964 14,263 10,832 5,272 4,113 4,318 3,325 9,590 7,438 8,867 6,167 7,223 4,929 16,090 11,096
Canadian registries 15-44 920 768 871 729 1,791 1,497 622 544 598 528 1,220 1,072 1,053 786 1,009 737 2,062 1,523
45-54 2,368 1,993 1,942 1,637 4,310 3,630 1,745 1,506 1,422 1,249 3,167 2,755 3,289 2,358 2,536 1,855 5,825 4,213
55-64 5,336 4,355 3,553 2,957 8,889 7,312 3,697 3,128 2,497 2,145 6,194 5,273 6,926 4,913 4,490 3,221 11,416 8,134
65-74 8,912 6,912 6,323 4,978 15,235 11,890 5,832 4,656 3,971 3,253 9,803 7,909 9,504 6,726 6,512 4,601 16,016 11,327
75-99 8,144 5,417 9,463 6,256 17,607 11,673 5,801 4,001 6,564 4,399 12,365 8,400 9,878 6,149 10,887 6,850 20,765 12,999
Total 25,680 19,445 22,152 16,557 47,832 36,002 17,697 13,835 15,052 11,574 32,749 25,409 30,650 20,932 25,434 17,264 56,084 38,196
Alberta 15-44 120 99 113 90 233 189 93 74 78 72 171 146 168 126 132 89 300 215
45-54 304 251 224 183 528 434 227 189 197 166 424 355 525 369 378 288 903 657
55-64 689 549 403 324 1,092 873 480 408 333 281 813 689 880 624 561 392 1,441 1,016
65-74 1,052 811 641 507 1,693 1,318 751 594 454 366 1,205 960 1,162 802 817 542 1,979 1,344
75-99 1,036 653 1,079 701 2,115 1,354 694 455 720 468 1,414 923 1,289 797 1,280 803 2,569 1,600
Total 3,201 2,363 2,460 1,805 5,661 4,168 2,245 1,720 1,782 1,353 4,027 3,073 4,024 2,718 3,168 2,114 7,192 4,832
British Columbia 15-44 163 137 161 140 324 277 104 94 131 116 235 210 178 135 179 140 357 275
45-54 444 372 359 299 803 671 336 291 275 237 611 528 586 424 521 386 1,107 810
55-64 1,015 837 687 582 1,702 1,419 693 590 491 421 1,184 1,011 1,358 956 894 656 2,252 1,612
65-74 1,824 1,453 1,235 1,000 3,059 2,453 1,156 918 779 647 1,935 1,565 1,987 1,403 1,306 947 3,293 2,350
75-99 1,874 1,273 1,974 1,355 3,848 2,628 1,349 957 1,445 998 2,794 1,955 2,241 1,437 2,272 1,424 4,513 2,861
Total 5,320 4,072 4,416 3,376 9,736 7,448 3,638 2,850 3,121 2,419 6,759 5,269 6,350 4,355 5,172 3,553 11,522 7,908
Manitoba 15-44 71 63 44 36 115 99 44 35 36 30 80 65 61 46 69 50 130 96
45-54 156 127 122 103 278 230 99 90 78 69 177 159 202 139 144 99 346 238
55-64 333 283 221 191 554 474 227 175 143 118 370 293 434 295 257 178 691 473
65-74 571 443 414 322 985 765 321 262 244 202 565 464 478 332 348 238 826 570
75-99 602 401 720 474 1,322 875 433 293 470 317 903 610 636 397 749 466 1,385 863
Total 1,733 1,317 1,521 1,126 3,254 2,443 1,124 855 971 736 2,095 1,591 1,811 1,209 1,567 1,031 3,378 2,240
Men Women Persons
Table 5: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: colorectal cancer
1995-99 2000-02 2005-07
a
Men Women Persons Men Women Persons





















Table 5: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: colorectal cancer
1995-99 2000-02 2005-07
a
Men Women Persons Men Women Persons
Ontario 15-44 566 469 553 463 1,119 932 381 341 353 310 734 651 646 479 629 458 1,275 937
45-54 1,464 1,243 1,237 1,052 2,701 2,295 1,083 936 872 777 1,955 1,713 1,976 1,426 1,493 1,082 3,469 2,508
55-64 3,299 2,686 2,242 1,860 5,541 4,546 2,297 1,955 1,530 1,325 3,827 3,280 4,254 3,038 2,778 1,995 7,032 5,033
65-74 5,465 4,205 4,033 3,149 9,498 7,354 3,604 2,882 2,494 2,038 6,098 4,920 5,877 4,189 4,041 2,874 9,918 7,063
75-99 4,632 3,090 5,690 3,726 10,322 6,816 3,325 2,296 3,929 2,616 7,254 4,912 5,712 3,518 6,586 4,157 12,298 7,675
Total 15,426 11,693 13,755 10,250 29,181 21,943 10,690 8,410 9,178 7,066 19,868 15,476 18,465 12,650 15,527 10,566 33,992 23,216
Denmark 15-44 185 156 201 163 386 319 116 93 106 89 222 182 206 145 200 137 406 282
45-54 693 520 615 497 1,308 1,017 448 369 372 321 820 690 747 505 649 489 1,396 994
55-64 1,634 1,235 1,309 1,011 2,943 2,246 1,136 914 876 727 2,012 1,641 2,161 1,502 1,671 1,161 3,832 2,663
65-74 2,571 1,740 2,347 1,679 4,918 3,419 1,725 1,225 1,372 967 3,097 2,192 3,127 2,087 2,319 1,566 5,446 3,653
75-99 3,016 1,662 3,822 2,188 6,838 3,850 1,941 1,073 2,344 1,334 4,285 2,407 3,147 1,725 3,791 2,080 6,938 3,805
Total 8,099 5,313 8,294 5,538 16,393 10,851 5,366 3,674 5,070 3,438 10,436 7,112 9,388 5,964 8,630 5,433 18,018 11,397
Norway 15-44 158 125 211 182 369 307 115 97 123 108 238 205 216 155 242 188 458 343
45-54 540 440 564 480 1,104 920 333 265 355 305 688 570 598 448 563 416 1,161 864
55-64 1,201 970 1,064 906 2,265 1,876 860 715 748 640 1,608 1,355 1,596 1,141 1,337 957 2,933 2,098
65-74 2,382 1,828 2,017 1,593 4,399 3,421 1,413 1,068 1,164 938 2,577 2,006 2,265 1,545 1,965 1,390 4,230 2,935
75-99 2,840 1,808 3,726 2,401 6,566 4,209 1,988 1,215 2,419 1,567 4,407 2,782 3,150 1,982 3,828 2,344 6,978 4,326
Total 7,121 5,171 7,582 5,562 14,703 10,733 4,709 3,360 4,809 3,558 9,518 6,918 7,825 5,271 7,935 5,295 15,760 10,566
Swedish regions 15-44 82 70 72 63 154 133 74 63 66 61 140 124 129 94 107 79 236 173
45-54 276 236 238 210 514 446 217 186 168 143 385 329 311 234 310 230 621 464
55-64 623 514 494 402 1,117 916 567 495 429 363 996 858 1,024 741 849 621 1,873 1,362
65-74 1,223 982 1,006 822 2,229 1,804 890 727 751 607 1,641 1,334 1,571 1,124 1,246 864 2,817 1,988
75-99 1,595 1,102 1,773 1,265 3,368 2,367 1,250 871 1,374 987 2,624 1,858 2,111 1,384 2,292 1,506 4,403 2,890
Total 3,799 2,904 3,583 2,762 7,382 5,666 2,998 2,342 2,788 2,161 5,786 4,503 5,146 3,577 4,804 3,300 9,950 6,877
UK-England 15-44 1,580 1,265 1,462 1,184 3,042 2,449 1,028 842 968 833 1,996 1,675 1,891 1,317 1,809 1,243 3,700 2,560
45-54 5,274 4,165 4,100 3,310 9,374 7,475 3,077 2,449 2,485 2,074 5,562 4,523 4,959 3,522 3,919 2,761 8,878 6,283
55-64 13,577 10,273 8,667 6,737 22,244 17,010 8,475 6,695 5,358 4,321 13,833 11,016 14,627 10,085 9,512 6,410 24,139 16,495
65-74 24,147 16,619 17,343 12,099 41,490 28,718 14,424 10,411 9,741 7,056 24,165 17,467 23,409 15,191 15,335 10,065 38,744 25,256
75-99 24,570 13,204 29,556 15,138 54,126 28,342 16,929 9,382 18,353 9,822 35,282 19,204 27,105 14,836 27,481 14,610 54,586 29,446
Total 69,148 45,526 61,128 38,468 130,276 83,994 43,933 29,779 36,905 24,106 80,838 53,885 71,991 44,951 58,056 35,089 130,047 80,040
UK-Northern Ireland 15-44 73 62 69 56 142 118 34 30 39 35 73 65 81 43 59 33 140 76
45-54 197 158 158 135 355 293 118 96 99 86 217 182 204 144 177 122 381 266
55-64 437 356 382 306 819 662 323 261 233 197 556 458 557 378 345 225 902 603
65-74 791 559 599 447 1,390 1,006 451 335 327 252 778 587 867 555 577 375 1,444 930
75-99 759 425 965 549 1,724 974 445 251 521 321 966 572 828 448 845 440 1,673 888
Total 2,257 1,560 2,173 1,493 4,430 3,053 1,371 973 1,219 891 2,590 1,864 2,537 1,568 2,003 1,195 4,540 2,763
UK-Wales 15-44 122 89 108 92 230 181 68 58 60 53 128 111 122 85 112 81 234 166
45-54 386 310 276 218 662 528 230 186 170 139 400 325 330 223 284 190 614 413
55-64 1,006 750 603 455 1,609 1,205 598 457 356 279 954 736 1,075 701 690 457 1,765 1,158
65-74 1,822 1,190 1,191 825 3,013 2,015 1,063 749 642 474 1,705 1,223 1,697 1,093 1,033 645 2,730 1,738
75-99 1,759 911 2,109 1,028 3,868 1,939 1,168 659 1,216 634 2,384 1,293 1,965 1,086 1,748 905 3,713 1,991
Total 5,095 3,250 4,287 2,618 9,382 5,868 3,127 2,109 2,444 1,579 5,571 3,688 5,189 3,188 3,867 2,278 9,056 5,466
a
 No. of patients included in the period analyses (see text and Figure 1) for 2005-07 are those who were diagnosed during 2005-07 and those who were diagnosed earlier but were alive on 1 January 2005




















Australian registries 15-44 232 119 218 127 450 246 136 68 141 84 277 152 213 115 222 126 435 241
45-54 1,080 425 714 345 1,794 770 601 269 461 251 1,062 520 872 351 787 372 1,659 723
55-64 3,076 1,242 1,408 649 4,484 1,891 1,854 756 1,033 514 2,887 1,270 2,610 1,144 1,780 867 4,390 2,011
65-74 6,292 2,246 2,642 1,032 8,934 3,278 3,377 1,261 1,554 642 4,931 1,903 4,301 1,706 2,349 971 6,650 2,677
75-99 4,777 1,189 2,388 636 7,165 1,825 3,271 947 1,878 531 5,149 1,478 4,998 1,425 2,969 881 7,967 2,306
Total 15,457 5,221 7,370 2,789 22,827 8,010 9,239 3,301 5,067 2,022 14,306 5,323 12,994 4,741 8,107 3,217 21,101 7,958
New South Wales 15-44 140 68 138 79 278 147 78 43 88 54 166 97 114 58 127 68 241 126
45-54 608 238 427 207 1,035 445 388 178 274 145 662 323 495 198 457 224 952 422
55-64 1,790 711 805 369 2,595 1,080 1,067 427 584 294 1,651 721 1,522 675 1,076 545 2,598 1,220
65-74 3,633 1,274 1,524 612 5,157 1,886 1,973 746 872 354 2,845 1,100 2,484 997 1,352 551 3,836 1,548
75-99 2,740 688 1,267 350 4,007 1,038 1,878 526 1,026 307 2,904 833 2,809 763 1,677 487 4,486 1,250
Total 8,911 2,979 4,161 1,617 13,072 4,596 5,384 1,920 2,844 1,154 8,228 3,074 7,424 2,691 4,689 1,875 12,113 4,566
Victoria 15-44 92 51 80 48 172 99 58 25 53 30 111 55 99 57 95 58 194 115
45-54 472 187 287 138 759 325 213 91 187 106 400 197 377 153 330 148 707 301
55-64 1,286 531 603 280 1,889 811 787 329 449 220 1,236 549 1,088 469 704 322 1,792 791
65-74 2,659 972 1,118 420 3,777 1,392 1,404 515 682 288 2,086 803 1,817 709 997 420 2,814 1,129
75-99 2,037 501 1,121 286 3,158 787 1,393 421 852 224 2,245 645 2,189 662 1,292 394 3,481 1,056
Total 6,546 2,242 3,209 1,172 9,755 3,414 3,855 1,381 2,223 868 6,078 2,249 5,570 2,050 3,418 1,342 8,988 3,392
Canadian registries 15-44 629 273 745 366 1,374 639 369 178 476 254 845 432 398 205 544 329 942 534
45-54 2,516 983 2,407 1,190 4,923 2,173 1,615 625 1,557 783 3,172 1,408 2,023 820 2,479 1,172 4,502 1,992
55-64 6,872 2,691 4,958 2,318 11,830 5,009 4,008 1,523 3,268 1,601 7,276 3,124 5,671 2,257 5,269 2,399 10,940 4,656
65-74 12,089 4,308 7,690 3,184 19,779 7,492 6,971 2,576 4,840 2,047 11,811 4,623 9,005 3,469 7,459 3,224 16,464 6,693
75-99 9,081 2,477 6,329 1,991 15,410 4,468 6,061 1,692 4,991 1,547 11,052 3,239 8,982 2,588 7,848 2,700 16,830 5,288
Total 31,187 10,732 22,129 9,049 53,316 19,781 19,024 6,594 15,132 6,232 34,156 12,826 26,079 9,339 23,599 9,824 49,678 19,163
Alberta 15-44 73 21 86 43 159 64 41 57 20 98 38 43 20 80 53 123 73
45-54 306 97 307 150 613 247 205 57 183 83 388 140 276 108 335 136 611 244
55-64 829 305 656 287 1,485 592 460 163 434 181 894 344 720 272 784 360 1,504 632
65-74 1,444 463 880 320 2,324 783 840 280 615 245 1,455 525 1,152 415 954 407 2,106 822
75-99 1,189 283 743 233 1,932 516 795 199 634 190 1,429 389 1,198 333 994 343 2,192 676
Total 3,841 1,169 2,672 1,033 6,513 2,202 2,341 717 1,923 719 4,264 1,436 3,389 1,148 3,147 1,299 6,536 2,447
British Columbia 15-44 129 51 167 83 296 134 62 85 43 147 75 55 28 86 49 141 77
45-54 487 175 530 241 1,017 416 285 97 353 171 638 268 380 149 506 248 886 397
55-64 1,343 508 968 427 2,311 935 712 248 652 289 1,364 537 1,110 385 1,081 486 2,191 871
65-74 2,382 841 1,609 634 3,991 1,475 1,354 491 961 387 2,315 878 1,779 658 1,615 680 3,394 1,338
75-99 2,002 493 1,541 433 3,543 926 1,328 334 1,185 364 2,513 698 1,950 544 1,759 579 3,709 1,123
Total 6,343 2,068 4,815 1,818 11,158 3,886 3,741 1,202 3,236 1,254 6,977 2,456 5,274 1,764 5,047 2,042 10,321 3,806
Manitoba 15-44 20 13 29 49 23 15 5 26 16 41 21 17 12 27 18 44 30
45-54 129 48 140 65 269 113 80 87 51 167 79 133 47 145 74 278 121
55-64 397 148 300 158 697 306 248 94 235 119 483 213 316 127 338 151 654 278
65-74 664 245 457 199 1,121 444 377 149 289 144 666 293 580 203 454 213 1,034 416
75-99 585 202 393 156 978 358 399 141 357 140 756 281 602 191 574 240 1,176 431
Total 1,795 656 1,319 588 3,114 1,244 1,119 417 994 470 2,113 887 1,648 580 1,538 696 3,186 1,276
Men Women Persons
Table 6: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: lung cancer
1995-99 2000-02 2005-07
a
Men Women Persons Men Women Persons





















Table 6: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, age, sex, country and jurisdiction: lung cancer
1995-99 2000-02 2005-07
a
Men Women Persons Men Women Persons
Ontario 15-44 407 188 463 230 870 418 251 123 308 175 559 298 283 145 351 209 634 354
45-54 1,594 663 1,430 734 3,024 1,397 1,045 443 934 478 1,979 921 1,234 516 1,493 714 2,727 1,230
55-64 4,303 1,730 3,034 1,446 7,337 3,176 2,588 1,018 1,947 1,012 4,535 2,030 3,525 1,473 3,066 1,402 6,591 2,875
65-74 7,599 2,759 4,744 2,031 12,343 4,790 4,400 1,656 2,975 1,271 7,375 2,927 5,494 2,193 4,436 1,924 9,930 4,117
75-99 5,305 1,499 3,652 1,169 8,957 2,668 3,539 1,018 2,815 853 6,354 1,871 5,232 1,520 4,521 1,538 9,753 3,058
Total 19,208 6,839 13,323 5,610 32,531 12,449 11,823 4,258 8,979 3,789 20,802 8,047 15,768 5,847 13,867 5,787 29,635 11,634
Denmark 15-44 177 61 186 74 363 135 113 48 100 55 213 103 111 51 145 58 256 109
45-54 852 279 840 321 1,692 600 517 192 498 205 1,015 397 601 250 760 314 1,361 564
55-64 2,262 656 1,773 613 4,035 1,269 1,414 478 1,150 468 2,564 946 2,123 740 1,908 784 4,031 1,524
65-74 3,698 883 2,461 638 6,159 1,521 2,374 652 1,695 539 4,069 1,191 2,901 964 2,456 888 5,357 1,852
75-99 2,645 412 1,590 243 4,235 655 1,811 333 1,300 254 3,111 587 2,438 505 1,976 441 4,414 946
Total 9,634 2,291 6,850 1,889 16,484 4,180 6,229 1,703 4,743 1,521 10,972 3,224 8,174 2,510 7,245 2,485 15,419 4,995
Norway 15-44 120 67 100 45 220 112 56 62 118 70 34 82 45 152 79
45-54 602 248 437 173 1,039 421 338 118 283 137 621 255 392 165 368 173 760 338
55-64 1,185 399 692 277 1,877 676 803 266 558 220 1,361 486 1,314 491 1,013 423 2,327 914
65-74 2,366 661 1,143 371 3,509 1,032 1,314 395 769 262 2,083 657 1,693 637 1,177 460 2,870 1,097
75-99 1,912 420 856 178 2,768 598 1,390 278 677 152 2,067 430 1,868 470 1,169 308 3,037 778
Total 6,185 1,795 3,228 1,044 9,413 2,839 3,901 1,081 2,349 801 6,250 1,882 5,337 1,797 3,809 1,409 9,146 3,206
Swedish regions 15-44 40 55 26 95 43 18 24 42 47 22 49 27 96 49
45-54 265 107 320 144 585 251 126 49 169 76 295 125 154 69 212 105 366 174
55-64 612 211 517 220 1,129 431 382 149 363 169 745 318 637 258 764 331 1,401 589
65-74 1,191 400 668 287 1,859 687 589 204 408 156 997 360 934 366 775 319 1,709 685
75-99 915 213 542 153 1,457 366 552 116 375 107 927 223 885 271 731 225 1,616 496
Total 3,023 948 2,102 830 5,125 1,778 1,667 524 1,339 523 3,006 1,047 2,657 986 2,531 1,007 5,188 1,993
UK-England 15-44 1,046 354 877 343 1,923 697 602 244 550 245 1,152 489 776 298 784 354 1,560 652
45-54 5,660 1,725 3,794 1,307 9,454 3,032 3,118 970 2,507 926 5,625 1,896 3,510 1,170 3,129 1,240 6,639 2,410
55-64 16,687 4,550 8,635 2,654 25,322 7,204 9,931 3,020 5,870 1,997 15,801 5,017 12,701 4,138 9,230 3,279 21,931 7,417
65-74 34,890 7,819 19,574 4,482 54,464 12,301 18,358 4,613 10,946 2,969 29,304 7,582 20,910 6,147 14,008 4,440 34,918 10,587
75-99 32,544 4,871 19,472 3,002 52,016 7,873 20,647 3,596 14,216 2,595 34,863 6,191 25,202 5,012 19,276 4,027 44,478 9,039
Total 90,827 19,319 52,352 11,788 143,179 31,107 52,656 12,443 34,089 8,732 86,745 21,175 63,099 16,765 46,427 13,340 109,526 30,105
UK-Northern Ireland 15-44 46 19 28 74 31 13 6 18 11 31 17 32 14 30 16 62 30
45-54 186 64 131 38 317 102 109 39 77 186 59 131 50 113 37 244 87
55-64 491 134 294 98 785 232 332 101 209 72 541 173 482 151 312 109 794 260
65-74 1,079 264 598 162 1,677 426 597 158 354 71 951 229 744 201 460 145 1,204 346
75-99 808 152 529 104 1,337 256 485 86 338 71 823 157 683 140 507 130 1,190 270
Total 2,610 633 1,580 414 4,190 1,047 1,536 390 996 245 2,532 635 2,072 556 1,422 437 3,494 993
UK-Wales 15-44 49 18 60 28 109 46 33 14 29 62 26 56 22 46 20 102 42
45-54 340 99 276 99 616 198 204 59 165 71 369 130 238 75 244 105 482 180
55-64 1,140 297 592 165 1,732 462 658 186 448 150 1,106 336 953 296 708 246 1,661 542
65-74 2,372 477 1,345 270 3,717 747 1,265 293 792 198 2,057 491 1,513 430 1,003 295 2,516 725
75-99 2,106 277 1,187 158 3,293 435 1,376 206 894 141 2,270 347 1,702 293 1,313 277 3,015 570
Total 6,007 1,168 3,460 720 9,467 1,888 3,536 758 2,328 572 5,864 1,330 4,462 1,116 3,314 943 7,776 2,059
a
 No. of patients included in the period analyses (see text and Figure 1) for 2005-07 are those who were diagnosed during 2005-07 and those who were diagnosed earlier but were alive on 1 January 2005








Australian registries 15-44 4,297 4,229 2,845 2,807 4,929 3,961
45-54 7,487 7,361 4,885 4,802 8,525 6,734
55-64 6,901 6,692 5,069 4,954 9,427 7,327
65-74 6,562 6,242 4,115 3,931 6,790 5,274
75-99 5,507 4,712 3,670 3,184 6,317 4,679
Total 30,754 29,236 20,584 19,678 35,988 27,975
New South Wales 15-44 2,437 2,395 1,630 1,606 2,779 2,254
45-54 4,264 4,193 2,776 2,730 4,858 3,819
55-64 3,979 3,871 2,961 2,898 5,575 4,354
65-74 3,712 3,531 2,356 2,241 3,861 3,006
75-99 3,111 2,662 2,145 1,883 3,663 2,704
Total 17,503 16,652 11,868 11,358 20,736 16,137
Victoria 15-44 1,860 1,834 1,215 1,201 2,150 1,707
45-54 3,223 3,168 2,109 2,072 3,667 2,915
55-64 2,922 2,821 2,108 2,056 3,852 2,973
65-74 2,850 2,711 1,759 1,690 2,929 2,268
75-99 2,396 2,050 1,525 1,301 2,654 1,975
Total 13,251 12,584 8,716 8,320 15,252 11,838
Canadian registries 15-44 7,442 7,261 4,524 4,438 8,056 6,418
45-54 12,213 11,930 8,445 8,271 14,797 11,619
55-64 11,814 11,442 8,214 7,984 15,643 12,057
65-74 12,616 11,945 7,533 7,197 13,020 9,989
75-99 11,365 9,894 7,387 6,408 13,240 9,714
Total 55,450 52,472 36,103 34,298 64,756 49,797
Alberta 15-44 1,112 1,085 671 650 1,207 944
45-54 1,670 1,633 1,265 1,237 2,222 1,736
55-64 1,569 1,524 1,120 1,093 2,043 1,566
65-74 1,536 1,440 997 956 1,762 1,384
75-99 1,407 1,213 1,000 860 1,778 1,323
Total 7,294 6,895 5,053 4,796 9,012 6,953
British Columbia 15-44 1,505 1,469 904 895 1,604 1,274
45-54 2,577 2,517 1,792 1,755 2,994 2,390
55-64 2,494 2,419 1,647 1,600 3,228 2,476
65-74 2,730 2,606 1,508 1,448 2,663 2,022
75-99 2,651 2,382 1,626 1,412 2,860 2,094
Total 11,957 11,393 7,477 7,110 13,349 10,256
Manitoba 15-44 390 377 221 216 351 267
45-54 692 678 443 435 790 613
55-64 695 671 482 468 896 701
65-74 756 711 392 370 706 550
75-99 847 745 523 463 917 676
Total 3,380 3,182 2,061 1,952 3,660 2,807
Ontario 15-44 4,435 4,330 2,728 2,677 4,894 3,933
45-54 7,274 7,102 4,945 4,844 8,791 6,880
55-64 7,056 6,828 4,965 4,823 9,476 7,314
65-74 7,594 7,188 4,636 4,423 7,889 6,033
75-99 6,460 5,554 4,238 3,673 7,685 5,621
Total 32,819 31,002 21,512 20,440 38,735 29,781
Table 7: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, 
age, sex, country and jurisdiction: breast cancer (women)
1995-99 2000-02 2005-07
a








Table 7: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, 
age, sex, country and jurisdiction: breast cancer (women)
1995-99 2000-02 2005-07
a
Denmark 15-44 1,788 1,744 1,126 1,104 1,945 1,566
45-54 3,933 3,813 2,498 2,438 3,855 3,041
55-64 4,129 3,913 3,062 2,918 5,694 4,420
65-74 3,681 3,358 2,332 2,178 4,464 3,435
75-99 3,783 3,029 2,588 2,111 4,389 3,120
Total 17,314 15,857 11,606 10,749 20,347 15,582
Norway 15-44 1,323 1,280 828 810 1,498 1,174
45-54 2,764 2,707 1,815 1,785 3,161 2,531
55-64 2,437 2,350 2,162 2,116 3,896 3,075
65-74 2,519 2,364 1,366 1,289 2,445 1,939
75-99 2,994 2,538 1,858 1,573 3,121 2,304
Total 12,037 11,239 8,029 7,573 14,121 11,023
Swedish regions 15-44 1,106 1,095 667 662 1,287 1,023
45-54 2,843 2,809 1,622 1,614 2,569 2,077
55-64 2,712 2,667 2,220 2,198 3,943 3,150
65-74 2,452 2,368 1,535 1,497 2,766 2,137
75-99 2,623 2,323 1,404 1,260 2,851 2,109
Total 11,736 11,262 7,448 7,231 13,416 10,496
UK-England 15-44 17,899 17,277 11,476 11,164 20,545 16,368
45-54 35,609 34,433 21,824 21,308 35,752 28,405
55-64 34,083 32,375 24,064 23,181 45,629 35,979
65-74 30,557 27,149 18,623 17,007 36,995 28,493
75-99 37,373 28,012 24,124 18,767 41,505 28,907
Total 155,521 139,246 100,111 91,427 180,426 138,152
UK-Northern Ireland 15-44 545 531 375 359 672 542
45-54 1,061 1,031 623 594 1,148 883
55-64 1,007 964 718 680 1,375 1,059
65-74 838 766 502 471 950 722
75-99 930 722 579 495 1,167 820
Total 4,381 4,014 2,797 2,599 5,312 4,026
UK-Wales 15-44 992 955 631 609 1,075 858
45-54 2,150 2,073 1,371 1,331 2,140 1,688
55-64 2,074 1,969 1,566 1,478 3,050 2,414
65-74 2,087 1,798 1,255 1,111 2,450 1,836
75-99 2,597 1,864 1,606 1,182 2,731 1,878
Total 9,900 8,659 6,429 5,711 11,446 8,674
a
 No. of patients included in the period analyses (see text and Figure 1) for 2005-07 are those who were diagnosed 
during 2005-07 and those who were diagnosed earlier but were alive on 1 January 2005








Australian registries 15-44 377 347 212 194 414 303
45-54 572 501 351 316 652 480
55-64 685 564 435 367 800 588
65-74 831 605 457 316 789 530
75-99 891 367 615 273 884 402
Total 3,356 2,384 2,070 1,466 3,539 2,303
New South Wales 15-44 222 205 121 111 223 159
45-54 320 272 203 182 388 293
55-64 391 323 252 217 463 338
65-74 450 320 256 179 427 290
75-99 497 212 339 159 512 232
Total 1,880 1,332 1,171 848 2,013 1,312
Victoria 15-44 155 142 91 83 191 144
45-54 252 229 148 134 264 187
55-64 294 241 183 150 337 250
65-74 381 285 201 137 362 240
75-99 394 155 276 114 372 170
Total 1,476 1,052 899 618 1,526 991
Canadian registries 15-44 963 883 614 575 1,085 827
45-54 1,357 1,171 930 829 1,614 1,168
55-64 1,472 1,202 1,097 902 1,931 1,386
65-74 1,969 1,409 1,093 813 1,876 1,239
75-99 1,716 830 1,256 613 1,807 846
Total 7,477 5,495 4,990 3,732 8,313 5,466
Alberta 15-44 206 194 100 91 109 80
45-54 186 163 101 91 206 154
55-64 175 143 122 97 193 142
65-74 204 141 106 82 168 109
75-99 201 80 123 49 187 78
Total 972 721 552 410 863 563
British Columbia 15-44 148 132 86 83 156 120
45-54 256 221 164 147 272 208
55-64 242 209 179 161 321 237
65-74 357 261 168 130 311 210
75-99 350 177 237 108 312 140
Total 1,353 1,000 834 629 1,372 915
Manitoba 15-44 48 39 27 26 46 32
45-54 56 51 44 35 87 59
55-64 79 66 51 42 103 77
65-74 97 73 75 56 94 62
75-99 117 41 80 44 104 44
Total 397 270 277 202 434 274
Ontario 15-44 561 518 401 376 774 595
45-54 859 736 621 556 1,049 747
55-64 976 784 745 602 1,314 930
65-74 1,311 934 744 545 1,303 858
75-99 1,048 532 816 412 1,204 584
Total 4,755 3,504 3,327 2,491 5,644 3,714
Table 8: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, 
age, sex, country and jurisdiction: ovarian cancer
1995-99 2000-02 2005-07
a








Table 8: Number of patients included in the analyses, both overall and 1-year survivors, by calendar period, 
age, sex, country and jurisdiction: ovarian cancer
1995-99 2000-02 2005-07
a
Denmark 15-44 275 238 161 149 199 152
45-54 568 487 317 268 431 336
55-64 716 550 452 366 774 540
65-74 807 491 511 341 709 449
75-99 667 239 426 172 577 243
Total 3,033 2,005 1,867 1,296 2,690 1,720
Norway 15-44 234 220 144 134 174 141
45-54 449 398 253 226 374 277
55-64 476 407 348 312 631 472
65-74 583 400 324 247 442 297
75-99 643 270 427 188 571 280







UK-England 15-44 2,741 2,437 1,588 1,458 2,852 2,132
45-54 4,375 3,554 2,508 2,085 3,646 2,624
55-64 5,898 4,166 3,891 2,975 6,229 4,298
65-74 6,739 3,828 4,059 2,453 5,838 3,519
75-99 6,272 2,160 4,423 1,511 5,790 2,252
Total 26,025 16,145 16,469 10,482 24,355 14,825
UK-Northern Ireland 15-44 115 107 81 76 120 106
45-54 163 125 84 68 135 103
55-64 203 150 116 92 215 138
65-74 206 123 132 92 204 125
75-99 159 61 123 38 151 60
Total 846 566 536 366 825 532
UK-Wales 15-44 166 146 100 90 163 124
45-54 305 227 168 146 243 173
55-64 424 283 276 208 448 291
65-74 534 279 305 152 429 253
75-99 497 172 312 112 414 152
Total 1,926 1,107 1,161 708 1,697 993
a
 No. of patients included in the period analyses (see text and Figure 1) for 2005-07 are those who were diagnosed 
during 2005-07 and those who were diagnosed earlier but were alive on 1 January 2005
Page 17 of 28
Table 9: Mean age at diagnosis (and standard deviation): cancer, jurisdicton and calendar period of diagnosis
Mean SD Mean SD Mean SD
Colorectal
Alberta 69.6 12.7 69.0 13.0 69.2 12.9
British Columbia 70.5 12.1 70.4 12.6 70.4 12.4
Manitoba 70.5 12.4 70.5 13.0 70.5 12.8
Ontario 69.5 12.2 69.5 12.5 69.5 12.4
Denmark 71.1 11.8 70.9 11.7 71.0 11.8
Norway 71.7 11.7 71.8 12.3 71.8 12.1
Swedish regions 72.0 11.5 71.9 11.8 72.0 11.7
UK-England 71.4 11.8 71.7 12.0 71.6 11.9
UK-Northern Ireland 70.4 12.0 70.2 11.9 70.2 12.0
UK-Wales 71.3 11.7 71.5 11.7 71.4 11.7
New South Wales 68.9 12.2 69.6 12.3 69.4 12.3
Victoria 69.3 12.1 69.9 12.6 69.7 12.4
Overall 70.8 11.9 71.0 12.2 70.9 12.1
Lung
Alberta 68.6 10.9 69.5 11.2 69.2 11.1
British Columbia 69.0 11.2 70.3 11.1 69.8 11.1
Manitoba 69.2 10.7 70.3 11.1 69.9 11.0
Ontario 68.3 10.8 69.2 11.1 68.9 11.0
Denmark 67.8 10.4 68.6 10.5 68.3 10.5
Norway 68.4 10.8 69.4 10.8 69.0 10.8
Swedish regions 68.1 10.5 68.9 10.6 68.6 10.6
UK-England 70.8 10.3 71.5 10.7 71.2 10.5
UK-Northern Ireland 69.8 10.3 70.0 10.4 69.9 10.4
UK-Wales 70.6 10.0 71.2 10.5 71.0 10.3
New South Wales 69.3 10.6 70.2 11.1 69.9 10.9
Victoria 69.8 10.5 70.7 11.1 70.4 10.9
Overall 69.9 10.5 70.6 10.8 70.3 10.7
Breast
Alberta 60.9 14.5 61.1 14.3 61.0 14.4
British Columbia 62.3 14.3 62.1 14.2 62.2 14.3
Manitoba 63.4 14.5 63.5 14.5 63.4 14.5
Ontario 61.6 14.3 61.6 14.1 61.6 14.1
Denmark 62.6 14.0 63.1 13.8 62.9 13.9
Norway 63.2 14.6 62.4 14.3 62.7 14.4
Swedish regions 62.7 13.9 62.7 13.6 62.7 13.7
UK-England 62.8 14.8 63.1 14.6 63.0 14.7
UK-Northern Ireland 61.6 14.6 62.0 14.6 61.8 14.6
UK-Wales 63.9 14.7 64.0 14.3 63.9 14.5
New South Wales 60.6 14.0 60.7 13.9 60.6 14.0
Victoria 60.7 14.2 60.5 14.1 60.6 14.1
Overall 62.4 14.6 62.5 14.4 62.5 14.4
Ovary
Alberta 59.7 16.7 62.0 15.7 61.1 16.1
British Columbia 63.9 15.3 63.9 15.4 63.9 15.3
Manitoba 64.9 15.7 64.7 15.4 64.8 15.5
Ontario 63.0 14.7 62.9 15.3 62.9 15.1
Denmark 63.4 13.7 64.6 13.5 64.2 13.6
Norway 64.3 14.4 65.0 14.6 64.7 14.6
Swedish regions - - -
UK-England 63.7 14.8 64.6 15.0 64.3 14.9
UK-Northern Ireland 61.3 15.1 62.6 15.5 62.1 15.4
UK-Wales 64.9 14.1 65.4 14.4 65.2 14.3
New South Wales 63.4 15.4 63.9 15.6 63.7 15.5
Victoria 64.2 15.3 64.5 15.5 64.4 15.4
Overall 63.6 14.8 64.3 15.0 64.0 14.9
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No. % No. %
Alberta 2,240 13.0 17,263 1,848 8.7 21,255
British Columbia 4,161 14.6 28,418 3,241 9.9 32,648
Manitoba 1,319 14.8 8,918 995 11.0 9,061
Ontario 6,823 8.1 84,362 4,508 4.9 92,597
Denmark 3,658 7.9 46,183 2,689 5.5 49,001
Norway 4,920 12.0 40,909 2,808 8.3 34,001
Swedish regions 2,961 12.6 23,554 2,844 8.8 32,395
UK-England 21,820 6.2 352,801 18,198 4.2 435,247
UK-Northern Ireland 417 3.5 11,891 227 1.8 12,464
UK-Wales 1,955 7.9 24,882 1,277 4.6 27,828
New South Wales 3,311 6.3 52,303 1,154 2.3 49,832
Victoria 5,049 12.5 40,521 2,009 5.4 37,021
Overall 58,634 8.0 732,005 41,798 5.0 833,350
No. % No. %
Alberta 2,756 14.5 19,031 294 12.0 2,454
British Columbia 4,579 14.7 31,123 377 10.4 3,640
Manitoba 1,646 17.9 9,202 155 13.5 1,146
Ontario 7,793 8.7 89,963 1,182 8.5 13,970
Denmark 4,173 8.9 47,151 652 8.4 7,773
Norway 3,321 12.1 27,383 664 10.8 6,159
Swedish regions 1,769 12.1 14,605 - - -
UK-England 28,109 7.5 376,496 4,741 6.8 69,485
UK-Northern Ireland 462 4.1 11,356 144 6.3 2,296
UK-Wales 2,465 9.6 25,742 490 9.8 5,003
New South Wales 2,635 7.3 36,251 316 6.1 5,151
Victoria 3,772 14.0 27,027 422 10.6 3,982
Overall 63,480 8.9 715,330 9,437 7.8 121,059
Swedish regions - no ovarian cancer data
 Table 10: Number and percentage of adults (15-99 years) diagnosed during 1995-2007 whose cancer was a second 
or higher-order primary: by cancer and jurisdiction 
Colorectal cancer Breast cancer
 Second and higher-
order primaries  All
primaries 
 Second and higher-
order primaries  All
primaries 
Lung cancer Ovarian cancer
 Second and higher-
order primaries  All
primaries 
 Second and higher-
order primaries  All
primaries 
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Table 11: Number and percentage of patients dying within a month of diagnosis, by period of diagnosis and jurisdiction
Colorectal  No.  %  No.  %  No.  % 
Alberta 398 7.0 777 6.8 1,175 6.9
British Columbia 500 5.1 983 5.3 1,483 5.3
Manitoba 184 5.7 321 5.7 505 5.7
Ontario 2,732 9.4 4,388 8.0 7,120 8.5
Denmark
1
- - 1,252 8.1 1,252 8.1
Norway 746 5.1 1,517 5.8 2,263 5.6
Swedish regions 343 4.6 643 4.0 986 4.2
UK-England 16,383 12.6 22,111 10.0 38,494 11.0
UK-Northern Ireland 391 8.8 506 6.9 897 7.6
UK-Wales 1,173 12.5 1,521 9.9 2,694 10.9
New South Wales
2
- - - - - -
Victoria 834 5.8 1,197 4.6 2,031 5.0
Overall 23,684 10.4 35,216 8.4 58,900 9.1
Overall excluding New South Wales and Denmark 23,684 10.4 33,964 8.5 57,648 9.2
Lung
Alberta 1,246 19.1 2,406 19.4 3,652 19.3
British Columbia 1,834 16.4 3,124 15.8 4,958 16.0
Manitoba 410 13.2 896 14.9 1,306 14.3
Ontario 7,776 23.9 13,951 24.5 21,727 24.3
Denmark
1
- - 2,499 15.9 2,499 15.9
Norway 1,304 13.9 2,748 15.4 4,052 14.9
Swedish regions 828 16.2 1,046 11.1 1,874 12.8
UK-England 37,635 26.3 53,415 23.1 91,050 24.3
UK-Northern Ireland 904 21.6 1,457 20.5 2,361 20.9
UK-Wales 2,812 29.7 3,923 24.3 6,735 26.3
New South Wales
2
- - - - - -
Victoria 1,409 14.4 2,472 14.5 3,881 14.5
Overall 56,158 24.0 87,937 21.4 144,095 22.4
Overall excluding New South Wales and Denmark 56,158 24.0 85,438 21.7 141,596 22.5
Breast
Alberta 83 1.1 118 0.9 201 1.0
British Columbia 86 0.7 171 0.8 257 0.8
Manitoba 25 0.7 47 0.8 72 0.8
Ontario 565 1.7 883 1.5 1,448 1.6
Denmark
1
- - 156 1.0 156 1.0
Norway 90 0.7 180 0.8 270 0.8
Swedish regions 43 0.4 50 0.2 93 0.3
UK-England 5,279 3.4 5,686 2.1 10,965 2.5
UK-Northern Ireland 77 1.8 88 1.1 165 1.3
UK-Wales 424 4.3 491 2.8 915 3.3
New South Wales
2
- - - - - -
Victoria 148 1.1 215 0.9 363 1.0
Overall 6,820 2.6 8,085 1.7 14,905 2.0
Overall excluding New South Wales and Denmark 6,820 2.6 7,929 1.7 14,749 2.0
Ovary
Alberta 86 8.9 127 8.7 213 8.7
British Columbia 107 7.9 180 7.9 287 7.9
Manitoba 37 9.3 75 10.1 112 9.9
Ontario 497 10.5 892 9.8 1,389 10.0
Denmark
1
- - 156 6.9 156 6.9
Norway 139 5.8 246 6.6 385 6.3
Swedish regions - - - - - -
UK-England 3,275 12.6 5,142 11.9 8,417 12.2
UK-Northern Ireland 90 10.6 138 9.6 228 10.0
UK-Wales 246 12.8 394 12.9 640 12.9
New South Wales
2
- - - - - -
Victoria 130 8.8 193 7.8 323 8.2
Overall 4,607 11.5 7,543 10.8 12,150 11.1
Overall excluding New South Wales and Denmark 4,607 11.5 7,387 11.0 11,994 11.2
1
 Full dates were only collected from 2004 onwards
2
 Full dates were not collected by this registry
3
 Swedish regions - no ovarian cancer data
 1995-1999 2000-2007 Overall
















One year No. of patients 32,621 18,358 14,263 47,832 5,661 9,736 3,254 29,181 16,393 14,703 7,382 144,088 130,276 4,430 9,382
Age-standardised 80.0 80.3 79.6 79.1 77.6 80.7 79.8 78.7 71.7 78.6 81.8 70.2 70.2 74.3 68.3
15-44 years 87.0 87.6 86.3 83.7 81.3 85.6 86.2 83.4 82.8 83.3 86.4 80.6 80.6 83.2 78.8
45-54 years 85.8 84.8 87.2 84.5 82.6 83.9 83.1 85.3 78.2 83.7 87.1 80.2 80.1 82.9 80.1
55-64 years 83.6 83.7 83.4 83.1 80.8 84.2 86.4 82.9 77.3 83.6 82.7 77.4 77.3 81.8 75.7
65-74 years 80.9 81.7 79.9 80.1 80.0 82.3 79.8 79.4 71.8 79.9 82.9 71.2 71.2 74.7 68.8
75-99 years 72.1 72.6 71.4 71.5 69.7 73.9 71.7 70.9 62.0 70.2 76.6 57.0 57.0 62.2 54.6
Five years Age-standardised 60.0 61.2 58.4 58.1 56.3 59.8 57.6 58.0 48.2 56.9 58.5 47.8 47.8 51.1 45.9
15-44 years 66.2 69.2 62.6 60.8 58.5 60.2 67.5 60.8 58.0 58.4 60.6 56.4 56.6 55.3 54.2
45-54 years 63.9 63.7 64.1 61.4 58.8 61.7 57.1 62.3 50.7 57.0 60.8 53.2 53.1 57.4 52.8
55-64 years 62.4 63.2 61.3 59.6 58.5 59.5 58.6 59.9 49.9 62.1 60.3 52.4 52.3 56.2 51.7
65-74 years 60.9 62.4 59.1 59.3 59.7 62.1 59.3 58.3 48.9 59.0 59.2 48.4 48.5 52.0 44.7
75-99 years 53.9 55.5 52.1 53.9 49.4 56.9 52.8 53.8 42.7 50.2 55.0 39.2 39.2 42.6 37.6
No. of patients 24,926 14,094 10,832 36,002 4,168 7,448 2,443 21,943 10,851 10,733 5,666 92,915 83,994 3,053 5,868
Age-standardised 75.0 76.2 73.4 73.6 72.5 74.2 72.2 73.8 67.3 72.3 71.6 68.1 68.2 68.8 67.2
15-44 years 76.1 79.1 72.6 72.6 71.9 70.3 78.3 72.9 70.1 70.1 70.2 70.0 70.2 66.5 68.8
45-54 years 74.4 75.1 73.5 72.7 71.1 73.5 68.8 73.1 64.9 68.1 69.9 66.4 66.4 69.3 65.9
55-64 years 74.6 75.5 73.4 71.7 72.4 70.6 67.8 72.3 64.5 74.3 72.9 67.7 67.7 68.7 68.3
65-74 years 75.3 76.3 74.0 74.1 74.7 75.4 74.4 73.5 68.2 73.8 71.4 68.0 68.1 69.6 65.0
75-99 years 74.8 76.3 72.9 75.3 70.9 76.9 73.6 75.8 68.8 71.6 71.8 68.8 68.8 68.6 68.8
Lung cancer (persons)
One year No. of patients 22,827 13,072 9,755 53,316 6,513 11,158 3,114 32,531 16,484 9,413 5,125 156,836 143,179 4,190 9,467
Age-standardised 38.2 38.6 37.8 38.7 36.4 36.6 41.7 39.6 26.4 32.3 35.7 24.3 24.3 27.4 23.0
15-44 years 55.1 53.5 57.7 46.7 41.1 45.5 47.4 48.0 37.1 51.0 45.5 36.7 36.2 42.2 42.5
45-54 years 43.4 43.9 42.9 44.4 41.2 41.0 42.2 46.3 35.6 40.8 42.9 32.1 32.1 32.5 32.2
55-64 years 43.1 42.9 43.4 42.9 41.1 40.8 44.3 43.7 31.8 36.2 38.3 28.6 28.6 30.0 26.9
65-74 years 38.2 38.6 37.6 38.9 35.7 37.8 40.7 39.7 25.5 30.2 37.8 23.0 23.1 26.1 20.4
75-99 years 28.2 29.5 26.7 31.1 30.3 27.9 39.2 31.4 16.7 23.3 26.3 16.0 16.1 20.9 13.9
Five years Age-standardised 13.9 14.2 13.4 15.7 13.8 13.9 16.6 16.6 8.0 11.0 12.7 7.0 6.9 9.7 7.5
15-44 years 28.6 26.3 32.2 23.8 21.4 21.8 29.3 24.6 19.7 27.5 17.2 18.0 17.4 27.4 22.5
45-54 years 17.4 18.4 16.1 20.2 18.1 16.9 18.2 22.0 11.1 16.0 16.7 10.2 10.0 10.6 12.8
55-64 years 15.9 16.0 15.8 18.1 17.2 16.6 19.3 18.7 9.9 12.4 14.4 8.7 8.7 9.7 8.9
65-74 years 13.1 14.0 11.9 15.2 13.4 14.3 13.6 16.0 7.1 9.6 12.8 5.9 5.9 8.7 5.5
75-99 years 8.0 8.4 7.4 10.4 7.9 8.2 13.9 11.4 3.4 5.2 8.5 2.9 2.8 5.9 2.5
No. of patients 8,010 4,596 3,414 19,781 2,202 3,886 1,244 12,449 4,180 2,839 1,778 34,042 31,107 1,047 1,888
Age-standardised 35.1 35.9 34.0 39.9 37.0 37.2 39.5 41.3 28.6 32.1 35.1 26.9 26.6 33.8 29.2
15-44 years 51.9 49.2 55.9 51.0 52.0 48.0 61.8 51.2 53.2 53.9 37.8 48.9 47.9 65.0 52.9
45-54 years 40.0 41.9 37.6 45.6 43.8 41.3 43.3 47.4 31.2 39.1 38.9 31.9 31.3 32.6 39.9
55-64 years 36.9 37.3 36.4 42.3 41.8 40.7 43.4 42.7 31.2 34.2 37.4 30.5 30.2 32.4 33.0
65-74 years 34.3 36.3 31.6 39.2 37.6 37.9 33.4 40.3 28.0 31.8 33.8 25.8 25.5 33.2 26.9
75-99 years 28.3 28.6 27.8 33.6 26.2 29.4 35.6 36.3 20.3 22.5 32.3 17.9 17.5 28.5 18.3
Table 12: Number of patients, age-standardised and age-specific relative survival estimates (%) at 1 and 5 years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer 
and jurisdiction, cohort analysis for 1995-99
Australia Canada United Kingdom
Conditional 5-year
Conditional 5-year















Table 12: Number of patients, age-standardised and age-specific relative survival estimates (%) at 1 and 5 years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer 
and jurisdiction, cohort analysis for 1995-99
Australia Canada United Kingdom
Breast cancer (women)
One year No. of patients 30,754 17,503 13,251 55,450 7,294 11,957 3,380 32,819 17,314 12,037 11,736 169,802 155,521 4,381 9,900
Age-standardised 95.8 95.8 95.6 95.9 95.4 97.1 96.2 95.5 93.0 95.4 97.6 90.4 90.5 92.6 88.6
15-44 years 98.5 98.4 98.7 97.7 97.7 97.7 96.7 97.7 97.7 96.8 99.1 96.6 96.6 97.5 96.4
45-54 years 98.5 98.6 98.5 97.9 98.1 97.9 98.2 97.9 97.3 98.2 99.0 97.0 97.0 97.5 96.7
55-64 years 97.5 97.9 97.1 97.5 97.8 97.6 97.2 97.4 95.7 97.0 98.9 95.7 95.7 96.6 95.7
65-74 years 96.7 96.7 96.6 96.4 95.3 97.2 95.8 96.4 93.5 95.6 98.2 90.7 90.8 93.6 88.0
75-99 years 91.6 91.6 91.7 93.0 92.0 96.0 94.8 91.6 87.6 92.6 95.1 81.6 81.7 85.3 78.4
Five years Age-standardised 85.0 85.5 84.4 85.3 83.4 87.1 86.0 84.9 76.9 81.8 86.7 74.8 74.8 77.5 73.5
15-44 years 84.3 84.6 83.9 82.4 82.9 80.7 79.7 83.0 79.5 80.5 83.9 78.3 78.3 79.7 77.8
45-54 years 88.2 88.4 88.0 87.3 87.3 88.1 87.5 87.0 83.4 86.1 89.7 84.3 84.3 84.0 84.4
55-64 years 88.4 89.0 87.5 87.1 87.0 87.2 85.9 87.2 80.9 85.6 90.6 83.1 83.1 83.4 83.1
65-74 years 88.0 88.2 87.8 87.1 84.5 89.1 88.7 86.8 77.7 83.4 88.8 75.1 75.2 76.2 72.4
75-99 years 78.3 79.0 77.3 81.9 77.9 86.1 84.2 80.7 69.7 75.6 81.0 63.0 62.9 70.8 61.5
No. of patients 29,236 16,652 12,584 52,472 6,895 11,393 3,182 31,002 15,857 11,239 11,262 151,919 139,246 4,014 8,659
Age-standardised 88.8 89.1 88.2 88.9 87.3 89.7 89.4 88.9 82.6 85.6 88.8 82.5 82.4 83.6 82.7
15-44 years 85.6 86.0 85.0 84.3 84.9 82.6 82.4 85.0 81.4 83.1 84.6 81.0 81.0 81.8 80.8
45-54 years 89.5 89.7 89.4 89.2 89.0 90.0 89.0 88.9 85.7 87.7 90.6 86.9 86.9 86.2 87.3
55-64 years 90.6 90.9 90.2 89.4 89.0 89.3 88.4 89.6 84.5 88.2 91.6 86.8 86.8 86.3 86.9
65-74 years 91.0 91.1 90.9 90.4 88.6 91.7 92.5 90.1 83.1 87.3 90.5 82.8 82.9 81.4 82.2
75-99 years 85.4 86.2 84.3 88.1 84.7 89.7 88.8 88.1 79.6 81.6 85.2 77.2 77.0 83.0 78.4
Ovarian cancer
One year No. of patients 3,356 1,880 1,476 7,477 972 1,353 397 4,755 3,033 2,385 -       28,797 26,025 846 1,926
Age-standardised 70.4 70.4 70.4 71.8 69.4 74.0 68.9 71.9 63.4 70.4 -       59.6 59.8 62.8 56.6
15-44 years 92.1 92.4 91.7 91.8 94.3 89.3 81.2 92.4 86.6 94.1 -       89.1 89.0 93.1 88.0
45-54 years 87.8 85.3 91.0 86.5 87.9 86.5 91.2 85.9 86.1 88.9 -       80.9 81.5 77.0 74.7
55-64 years 82.9 83.2 82.4 82.2 82.4 87.0 84.1 80.9 77.6 86.1 -       71.0 71.2 74.5 67.3
65-74 years 74.1 72.6 76.0 72.9 71.0 74.5 76.4 72.5 62.3 69.9 -       57.7 57.9 61.2 53.2
75-99 years 44.4 46.5 41.7 51.4 43.9 54.3 37.1 53.4 38.4 45.0 -       36.6 36.5 41.8 36.5
Five years Age-standardised 36.1 35.9 36.4 38.2 41.4 35.1 32.7 39.0 31.5 37.2 -       32.6 32.5 39.0 31.5
15-44 years 73.0 71.0 75.9 74.0 84.5 65.9 56.4 73.7 62.3 72.6 -       73.0 73.0 73.5 72.1
45-54 years 53.5 53.1 54.0 53.8 58.6 52.9 48.8 53.4 45.5 53.7 -       48.3 48.4 48.0 47.3
55-64 years 43.3 42.1 44.8 43.9 44.7 46.0 41.8 43.4 36.9 46.8 -       36.5 36.5 41.7 33.0
65-74 years 34.7 35.7 33.6 33.2 39.3 27.0 36.5 33.8 27.2 33.3 -       27.4 27.1 39.1 27.4
75-99 years 15.8 15.8 15.7 23.5 23.4 19.8 9.1 26.4 18.4 18.1 -       18.4 18.3 24.5 17.9
No. of patients 2,384 1,332 1,052 5,495 721 1,000 270 3,504 2,005 1,695 -       17,818 16,145 566 1,107
Age-standardised 48.8 48.6 49.2 51.9 58.3 45.7 43.7 53.3 48.9 50.6 -       53.1 52.8 63.0 53.8
15-44 years 79.3 76.9 82.7 80.6 89.7 73.9 69.5 79.7 71.9 77.2 -       81.9 82.1 79.0 81.9
45-54 years 60.9 62.2 59.3 62.2 66.6 61.1 53.5 62.2 52.9 60.5 -       59.7 59.4 62.4 63.3
55-64 years 52.2 50.6 54.4 53.4 54.3 52.8 49.7 53.6 47.6 54.3 -       51.4 51.3 56.0 49.1
65-74 years 46.9 49.2 44.3 45.6 55.4 36.2 47.8 46.6 43.7 47.7 -       47.6 46.8 63.9 51.5
75-99 years 35.5 33.9 37.7 45.7 53.4 36.4 24.6 49.5 48.0 40.2 -       50.3 50.0 64.2 49.1
Some age-standardised estimates arise from imputed age-specific estimates (see text)
Patients included in conditional five-year survival estimates are those who survived at least one year after diagnosis (see text)
Patients included in the period analysis are those who were diagnosed during 2005-07, or diagnosed earlier but alive on 1 January 2005 (see text and Figure 1 in The Lancet article)
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One year No. of patients 21,665 12,075 9,590 32,749 4,027 6,759 2,095 19,868 10,436 9,518 5,786 88,999 80,838 2,590 5,571
Age-standardised 82.5 83.2 81.6 81.5 79.8 82.4 80.4 81.7 73.9 78.7 82.8 73.0 72.9 76.8 72.3
15-44 years 90.8 92.0 89.5 88.0 85.6 89.5 81.4 88.8 82.1 86.2 88.6 84.4 84.0 89.1 86.8
45-54 years 87.9 88.3 87.5 87.3 84.1 86.7 90.1 87.9 84.5 83.2 85.7 81.7 81.6 84.3 81.6
55-64 years 87.3 88.4 85.7 85.9 85.5 86.1 80.0 86.5 82.5 85.0 86.8 80.4 80.4 83.3 77.9
65-74 years 83.5 83.9 82.9 82.6 81.5 82.8 84.1 82.6 72.9 79.7 83.1 74.3 74.2 77.7 73.6
75-99 years 73.5 74.1 72.8 73.0 70.5 75.4 72.8 72.6 61.7 69.0 76.9 59.4 59.2 64.5 59.1
Five years Age-standardised 63.4 65.1 61.1 60.9 58.0 61.5 59.6 61.3 51.7 58.8 60.6 51.3 51.2 54.3 50.3
15-44 years 69.0 71.6 66.1 63.8 63.7 65.6 57.9 63.9 60.1 68.0 64.5 59.5 59.0 64.8 64.6
45-54 years 66.6 68.6 64.1 63.8 59.8 62.6 68.1 64.6 57.3 62.5 59.5 56.3 56.4 58.4 54.4
55-64 years 67.9 69.5 65.6 64.2 62.6 63.5 60.7 65.1 56.0 62.3 64.0 56.3 56.6 55.1 52.9
65-74 years 64.9 67.0 62.2 62.4 62.4 62.5 63.8 62.1 50.5 58.8 60.2 52.5 52.5 55.1 51.7
75-99 years 55.5 56.7 54.1 54.8 47.8 57.5 51.6 55.6 45.1 52.1 57.9 41.9 41.7 48.8 41.8
No. of patients 17,004 9,566 7,438 25,409 3,073 5,269 1,591 15,476 7,112 6,918 4,503 59,437 53,885 1,864 3,688
Age-standardised 76.7 78.2 74.9 74.7 72.5 74.8 74.0 75.2 70.1 74.7 73.3 70.3 70.3 71.1 69.7
15-44 years 76.0 77.9 73.8 72.5 74.5 73.3 71.1 72.0 73.2 78.9 72.7 70.6 70.2 72.7 74.4
45-54 years 75.7 77.7 73.3 73.1 71.1 72.2 75.6 73.5 67.8 75.1 69.4 68.9 69.1 69.3 66.7
55-64 years 77.8 78.6 76.6 74.7 73.2 73.8 75.8 75.3 67.9 73.3 73.8 70.1 70.4 66.2 67.9
65-74 years 77.7 79.8 75.1 75.5 76.5 75.5 75.9 75.2 69.2 73.8 72.5 70.7 70.7 70.9 70.2
75-99 years 75.5 76.5 74.3 75.0 67.9 76.3 70.8 76.5 73.1 75.6 75.4 70.6 70.5 75.6 70.8
Lung cancer (persons)
One year No. of patients 14,306 8,228 6,078 34,156 4,264 6,977 2,113 20,802 10,972 6,250 3,006 95,141 86,745 2,532 5,864
Age-standardised 40.9 41.5 39.9 39.7 36.3 37.5 44.1 40.5 31.3 32.2 36.6 27.5 27.5 28.3 25.9
15-44 years 55.2 58.9 49.5 51.3 39.7 50.7 51.1 53.4 48.6 45.7 49.6 42.9 42.5 55.4 42.3
45-54 years 49.6 49.8 49.2 44.6 37.5 42.1 47.4 46.7 39.3 41.1 42.5 33.8 33.8 31.8 35.3
55-64 years 44.8 44.9 44.6 43.4 39.8 39.6 44.6 45.2 37.3 36.0 43.1 31.9 32.0 32.5 30.6
65-74 years 40.0 40.6 39.3 40.1 38.1 38.7 45.1 40.5 30.1 32.3 36.8 26.2 26.4 24.8 24.3
75-99 years 31.5 32.2 30.7 31.3 30.5 29.6 39.7 31.0 20.4 22.3 25.7 18.8 18.9 20.5 16.1
Five years Age-standardised 15.1 16.2 13.6 15.9 13.1 14.0 19.4 16.7 9.6 11.0 11.6 8.1 8.0 9.7 7.6
15-44 years 32.0 34.1 29.0 25.1 19.8 22.2 17.3 27.4 22.2 0.0 0.0 21.5 21.3 32.9 19.8
45-54 years 19.8 21.3 17.4 20.2 17.1 18.0 19.4 21.6 13.1 17.0 14.4 10.3 10.2 11.0 11.2
55-64 years 15.6 15.7 15.5 17.9 14.9 14.8 21.7 18.9 11.1 13.8 15.3 9.5 9.6 10.7 8.6
65-74 years 14.2 15.6 12.4 15.4 12.7 14.6 21.0 15.7 8.8 10.8 10.8 7.1 7.1 7.8 6.3
75-99 years 9.6 10.8 8.0 10.8 8.8 8.9 16.7 11.2 4.8 4.9 7.4 3.7 3.7 4.8 3.7
No. of patients 5,323 3,074 2,249 12,826 1,436 2,456 887 8,047 3,224 1,882 1,047 23,140 21,175 635 1,330
Age-standardised 36.0 38.1 33.0 39.4 35.6 36.5 44.2 40.5 29.4 32.8 31.5 27.6 27.4 31.8 27.7
15-44 years 58.1 57.8 58.6 49.0 49.9 43.8 33.9 51.3 45.7 0.0 0.0 50.2 50.0 59.4 46.7
45-54 years 40.0 42.8 35.5 45.2 45.7 42.6 40.9 46.3 33.4 41.4 33.8 30.4 30.2 34.5 31.7
55-64 years 34.8 34.9 34.7 41.1 37.4 37.4 48.6 41.9 29.7 38.4 35.5 29.9 29.9 32.9 28.0
65-74 years 35.5 38.5 31.5 38.4 33.3 37.9 46.6 38.8 29.1 33.5 29.4 27.1 27.0 31.5 26.0
75-99 years 30.3 33.6 26.0 34.4 28.9 30.1 42.1 36.1 23.7 22.0 29.0 19.6 19.3 23.5 22.7
Table 13: Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: 
cancer and jurisdiction, cohort analysis for 2000-02
Australia Canada United Kingdom
Conditional 5-year
Conditional 5-year















Table 13: Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: 
cancer and jurisdiction, cohort analysis for 2000-02
Australia Canada United Kingdom
Breast cancer (women)
One year No. of patients 20,584 11,868 8,716 36,103 5,053 7,477 2,061 21,512 11,606 8,029 7,448 109,337 100,111 2,797 6,429
Age-standardised 96.3 96.5 96.0 96.2 95.9 96.5 96.4 96.0 94.3 95.8 98.4 92.4 92.5 95.0 89.8
15-44 years 98.8 98.6 98.9 98.2 96.9 99.0 97.8 98.2 98.1 97.9 99.3 97.3 97.4 95.8 96.6
45-54 years 98.5 98.5 98.5 98.2 98.0 98.2 98.4 98.2 98.0 98.6 99.7 97.8 97.9 95.6 97.4
55-64 years 98.2 98.4 98.0 97.8 98.1 97.8 97.6 97.7 96.1 98.4 99.5 96.8 97.0 95.4 95.0
65-74 years 96.9 96.5 97.4 97.1 97.2 97.7 96.0 97.0 95.6 95.9 99.1 93.0 93.1 95.8 90.3
75-99 years 92.7 93.6 91.3 92.5 91.7 93.1 94.7 92.2 89.1 92.0 96.2 85.0 85.0 93.5 80.5
Five years Age-standardised 87.0 87.4 86.5 86.4 84.9 87.5 83.9 86.6 81.5 83.8 89.3 78.8 78.8 81.6 76.7
15-44 years 86.7 87.0 86.2 85.8 84.9 88.1 86.5 85.2 85.9 83.6 89.6 81.9 82.0 77.5 82.0
45-54 years 89.3 89.7 88.9 88.8 86.6 90.0 90.5 88.9 87.0 90.7 92.7 87.2 87.4 79.9 86.4
55-64 years 90.8 90.8 90.7 88.8 89.2 88.9 86.3 88.9 84.4 89.7 93.0 87.1 87.3 82.0 85.4
65-74 years 89.2 89.5 88.9 89.2 88.3 89.8 83.7 89.7 83.0 85.2 93.1 79.5 79.6 80.6 77.8
75-99 years 81.0 81.9 79.8 80.8 77.4 82.9 78.9 81.0 74.5 74.9 81.0 67.3 67.1 84.0 63.4
No. of patients 19,678 11,358 8,320 34,298 4,796 7,110 1,952 20,440 10,749 7,573 7,231 99,737 91,427 2,599 5,711
Age-standardised 90.3 90.6 90.0 89.8 88.5 90.6 87.0 90.2 86.4 87.3 90.6 85.0 85.0 86.3 85.1
15-44 years 87.8 88.2 87.2 87.4 87.6 89.0 88.4 86.7 87.5 85.4 90.2 84.2 84.2 80.9 84.8
45-54 years 90.7 91.0 90.3 90.5 88.3 91.7 92.0 90.5 88.8 92.0 93.0 89.1 89.3 83.6 88.8
55-64 years 92.4 92.3 92.5 90.8 90.9 90.9 88.4 91.0 87.8 91.1 93.5 89.9 90.0 85.9 89.9
65-74 years 92.1 92.7 91.2 91.8 90.8 92.0 87.2 92.5 86.8 88.8 94.0 85.4 85.4 84.1 86.2
75-99 years 87.4 87.4 87.4 87.3 84.4 89.0 83.2 87.9 83.6 81.3 84.2 79.2 78.9 91.4 78.7
Ovarian cancer
One year No. of patients 2,070 1,171 899 4,990 552 834 277 3,327 1,867 1,496 -       18,166 16,469 536 1,161
Age-standardised 71.1 72.8 68.9 73.3 71.0 75.3 74.1 73.1 67.9 74.3 -       62.4 62.6 64.9 60.0
15-44 years 91.6 91.8 91.2 93.7 91.2 96.6 92.7 93.8 92.6 93.1 -       91.9 91.9 93.8 90.1
45-54 years 90.2 89.9 90.7 89.4 90.3 89.8 79.8 89.7 84.8 89.6 -       83.5 83.4 81.2 87.1
55-64 years 84.8 86.6 82.3 82.7 80.0 90.4 82.8 81.3 81.7 90.2 -       77.0 77.0 79.9 75.9
65-74 years 70.4 71.5 69.1 75.6 78.6 78.6 75.8 74.4 68.4 77.6 -       61.1 61.5 71.0 50.8
75-99 years 48.0 51.3 43.7 51.8 43.4 48.6 58.6 53.3 43.5 47.5 -       36.5 36.5 33.2 38.0
Five years Age-standardised 37.1 39.6 34.1 38.4 34.9 37.8 37.1 39.1 33.7 40.2 -       34.3 34.3 37.8 33.8
15-44 years 66.2 68.1 63.8 73.9 76.4 67.7 85.5 73.7 76.3 74.0 -       77.7 77.6 80.7 76.3
45-54 years 57.1 59.9 53.2 57.3 62.0 59.4 50.9 56.3 54.0 56.2 -       51.4 51.3 46.9 55.0
55-64 years 46.5 46.4 46.6 43.1 41.5 48.6 39.1 42.3 39.2 49.1 -       41.0 40.8 45.8 41.1
65-74 years 31.3 34.8 26.9 34.2 28.8 28.4 36.9 36.1 28.2 38.6 -       28.9 28.8 41.4 24.1
75-99 years 20.2 23.7 16.2 22.5 14.5 22.5 18.3 24.1 16.3 19.9 -       17.0 17.0 13.7 18.6
No. of patients 1,466 848 618 3,732 410 629 202 2,491 1,296 1,107 -       11,556 10,482 366 708
Age-standardised 50.4 53.0 47.0 50.9 46.4 49.1 48.1 52.2 47.2 52.2 -       52.8 52.6 55.0 53.9
15-44 years 72.3 74.1 69.9 78.8 83.8 70.1 92.2 78.6 82.3 79.5 -       84.6 84.5 86.0 84.7
45-54 years 63.3 66.7 58.6 64.1 68.6 66.1 63.8 62.8 63.6 62.8 -       61.6 61.6 57.8 63.2
55-64 years 54.8 53.6 56.6 52.1 51.8 53.8 47.2 52.0 47.9 54.4 -       53.2 53.0 57.3 54.2
65-74 years 44.5 48.7 39.0 45.3 36.7 36.1 48.7 48.5 41.3 49.8 -       47.3 46.8 58.3 47.5
75-99 years 42.2 46.1 37.0 43.4 33.5 46.3 31.2 45.2 37.4 41.9 -       46.7 46.6 41.3 48.8
Some age-standardised estimates arise from imputed age-specific estimates (see text)
Patients included in conditional five-year survival estimates are those who survived at least one year after diagnosis (see text)
Patients included in the period analysis are those who were diagnosed during 2005-07, or diagnosed earlier but alive on 1 January 2005 (see text and Figure 1 in The Lancet article)
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One year No. of patients 37,201 21,111 16,090 56,084 7,192 11,522 3,378 33,992 18,018 15,760 9,950 143,643 130,047 4,540 9,056
Age-standardised 84.9 84.7 85.1 83.5 80.4 84.3 82.1 83.9 77.7 82.4 83.8 74.7 74.7 76.2 73.6
15-44 years 89.5 87.1 92.2 92.1 90.2 91.7 90.9 92.8 87.9 89.3 85.1 82.6 82.5 82.6 84.2
45-54 years 90.4 90.3 90.5 89.1 86.4 90.3 88.3 89.5 86.5 88.6 90.0 83.8 83.9 86.8 80.2
55-64 years 89.5 89.0 90.3 87.9 84.9 88.6 87.6 88.4 83.6 86.6 86.7 81.5 81.6 82.3 79.6
65-74 years 86.4 86.7 85.9 84.5 81.3 85.5 81.2 85.0 80.8 83.8 84.5 76.6 76.6 78.4 74.9
75-99 years 76.4 76.5 76.3 74.5 71.2 75.5 73.8 74.9 63.7 73.3 77.9 61.8 61.8 63.3 62.1
Five years Age-standardised 65.9 66.4 65.5 63.7 58.3 64.0 63.3 64.9 55.8 62.0 62.6 53.6 53.7 55.2 52.3
15-44 years 71.2 69.4 73.4 68.8 64.3 68.3 74.1 69.2 62.3 69.6 66.0 59.3 59.1 59.0 62.8
45-54 years 68.1 68.0 68.3 66.1 66.2 66.2 64.3 66.1 61.6 63.0 63.0 58.1 58.3 53.2 58.4
55-64 years 68.5 67.2 70.4 67.4 61.1 67.3 67.3 68.8 57.8 63.5 66.2 58.3 58.6 56.7 53.9
65-74 years 68.2 69.1 67.0 65.6 61.8 66.4 62.9 66.5 58.1 63.6 63.3 55.8 55.7 59.0 54.6
75-99 years 59.5 61.5 57.0 56.7 47.8 56.9 57.4 58.7 47.9 57.1 58.3 44.5 44.4 50.1 43.8
No. of patients 25,520 14,424 11,096 38,196 4,832 7,908 2,240 23,216 11,397 10,566 6,877 88,269 80,040 2,763 5,466
Age-standardised 77.7 78.4 76.8 76.4 72.3 75.9 77.1 77.4 72.1 75.4 74.8 71.8 71.8 73.0 71.1
15-44 years 79.6 79.6 79.6 74.6 71.2 74.5 81.5 74.6 70.9 77.9 77.5 71.8 71.6 71.4 74.6
45-54 years 75.4 75.4 75.4 74.1 76.7 73.3 72.9 73.8 71.2 71.0 69.9 69.4 69.5 61.3 72.7
55-64 years 76.5 75.5 78.0 76.7 72.0 76.0 76.8 77.8 69.1 73.3 76.4 71.5 71.9 68.9 67.6
65-74 years 79.0 79.7 78.0 77.7 76.0 77.6 77.4 78.2 71.9 75.9 74.9 72.8 72.7 75.3 72.9
75-99 years 77.8 80.4 74.6 76.1 67.2 75.3 77.8 78.4 75.2 77.9 74.8 72.0 71.9 79.2 70.5
Lung cancer (persons)
One year No. of patients 21,101 12,113 8,988 49,678 6,536 10,321 3,186 29,635 15,419 9,146 5,188 120,796 109,526 3,494 7,776
Age-standardised 42.8 42.9 42.7 43.1 41.5 43.0 42.7 43.4 34.9 39.2 43.6 29.7 29.7 30.6 28.5
15-44 years 62.2 61.1 63.7 58.0 59.6 61.7 61.6 56.6 41.6 54.0 64.1 43.6 43.8 45.2 38.3
45-54 years 48.3 48.6 48.0 47.6 44.6 47.8 48.1 47.9 45.0 47.6 44.3 36.2 36.1 37.4 36.9
55-64 years 49.7 50.3 48.7 46.8 44.1 46.1 45.4 47.6 40.4 44.0 46.4 34.4 34.5 33.9 32.7
65-74 years 42.5 42.8 42.0 43.0 40.7 43.2 40.8 43.6 36.4 40.7 43.8 29.8 29.9 30.1 28.5
75-99 years 30.8 30.4 31.3 34.7 34.7 33.9 35.7 34.7 23.4 26.9 35.8 19.7 19.7 22.1 19.3
Five years Age-standardised 17.0 17.6 16.2 18.4 15.1 17.7 20.1 19.1 10.9 14.4 16.3 8.8 8.7 11.0 9.0
15-44 years 34.1 32.4 36.3 31.8 27.1 30.4 20.4 33.6 19.2 35.1 38.1 20.4 20.1 30.5 18.1
45-54 years 19.0 20.4 17.2 21.6 19.7 20.6 21.3 22.3 15.5 19.1 15.7 12.0 11.8 14.6 13.9
55-64 years 20.2 20.6 19.7 20.8 17.9 20.4 23.8 21.2 12.6 16.2 16.9 10.4 10.3 12.0 11.1
65-74 years 16.4 17.6 14.8 17.7 13.6 17.6 20.7 18.3 10.6 13.5 15.4 8.1 8.1 9.5 7.6
75-99 years 10.0 10.4 9.5 12.8 9.5 11.4 16.0 13.6 5.9 7.1 11.8 4.1 4.1 5.4 4.5
No. of patients 7,958 4,566 3,392 19,163 2,447 3,806 1,276 11,634 4,995 3,206 1,993 33,157 30,105 993 2,059
Age-standardised 38.6 40.1 36.6 42.1 35.4 40.3 47.4 43.5 30.3 35.0 36.5 28.2 27.9 33.8 30.2
15-44 years 54.9 53.1 57.0 54.7 45.5 49.3 33.1 59.3 46.2 64.9 59.4 46.8 45.9 67.5 47.3
45-54 years 39.3 42.0 35.9 45.5 44.2 43.1 44.2 46.6 34.4 40.0 35.4 33.1 32.6 39.0 37.5
55-64 years 40.7 41.0 40.5 44.4 40.5 44.2 52.6 44.5 31.1 36.7 36.4 30.3 29.9 35.3 33.8
65-74 years 38.6 41.1 35.2 41.2 33.4 40.6 50.7 42.0 29.1 33.1 35.0 27.2 27.1 31.5 26.7
75-99 years 32.6 34.4 30.4 36.8 27.5 33.6 44.9 39.0 25.3 26.4 33.0 21.1 20.8 24.5 23.6
Table 14: Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer 
and jurisdiction, period analysis for 2005-07
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Table 14: Number of patients, age-standardised and age-specific relative survival estimates (%) at one and five years, and at 5 years conditional on survival to the first anniversary of diagnosis: cancer 
and jurisdiction, period analysis for 2005-07
Australia Canada United Kingdom
Breast cancer (women)
One year No. of patients 35,988 20,736 15,252 64,756 9,012 13,349 3,660 38,735 20,347 14,121 13,416 197,184 180,426 5,312 11,446
Age-standardised 96.7 96.5 97.1 96.3 95.9 97.1 96.7 96.1 95.0 96.6 98.0 94.2 94.3 95.0 93.4
15-44 years 98.7 98.6 98.7 98.5 98.1 98.8 96.6 98.6 99.1 98.1 99.4 98.2 98.2 97.7 97.9
45-54 years 98.8 98.5 99.2 98.2 98.2 99.1 98.6 97.9 98.2 99.3 99.1 98.2 98.2 98.0 98.1
55-64 years 98.7 98.6 98.7 97.7 97.4 98.0 97.3 97.7 97.9 98.5 99.1 97.5 97.5 98.7 97.4
65-74 years 97.5 97.7 97.4 97.2 97.3 97.1 98.1 97.1 95.9 97.8 98.1 96.1 96.1 96.1 95.4
75-99 years 93.1 92.2 94.3 93.1 91.7 95.1 94.2 92.6 89.5 92.3 96.3 87.2 87.2 89.2 85.0
Five years Age-standardised 88.1 87.8 88.5 86.3 82.6 89.1 86.8 86.4 82.4 85.5 88.5 81.6 81.6 84.1 81.0
15-44 years 87.9 87.9 87.9 87.0 89.2 87.3 83.5 86.5 87.4 85.1 91.4 84.1 84.1 83.4 83.9
45-54 years 90.5 90.5 90.4 89.4 89.2 90.5 91.6 88.9 88.5 91.4 91.9 88.3 88.4 85.5 89.0
55-64 years 91.5 92.0 90.8 89.0 88.0 89.9 88.4 89.0 86.6 91.6 92.1 88.8 88.8 87.3 88.9
65-74 years 90.6 91.2 89.7 88.8 86.1 90.8 89.4 88.8 83.8 88.6 90.5 84.5 84.4 86.5 84.1
75-99 years 82.1 79.9 84.9 80.3 70.3 86.7 81.9 80.7 73.9 75.1 81.4 69.8 69.6 78.7 67.5
No. of patients 27,975 16,137 11,838 49,797 6,953 10,256 2,807 29,781 15,582 11,023 10,496 150,852 138,152 4,026 8,674
Age-standardised 91.0 90.9 91.2 89.6 86.0 91.8 89.7 89.8 86.6 88.4 90.2 86.4 86.4 88.9 86.4
15-44 years 89.1 89.1 89.1 88.3 90.9 88.4 86.4 87.8 88.2 86.7 91.9 85.6 85.6 85.3 85.7
45-54 years 91.6 92.0 91.1 91.1 90.9 91.4 92.9 90.9 90.1 92.1 92.7 90.0 90.0 87.2 90.7
55-64 years 92.7 93.2 92.0 91.1 90.4 91.8 90.9 91.1 88.5 92.9 93.0 91.0 91.1 88.5 91.2
65-74 years 92.8 93.4 92.1 91.4 88.5 93.5 91.1 91.5 87.3 90.7 92.3 87.9 87.8 90.0 88.2
75-99 years 88.2 86.6 90.3 86.2 76.7 91.2 86.9 87.1 82.6 81.3 84.5 80.1 79.8 89.8 79.4
Ovarian cancer
One year No. of patients 3,539 2,013 1,526 8,313 863 1,372 434 5,644 2,690 2,192 -       26,877 24,355 825 1,697
Age-standardised 73.5 73.3 73.7 75.2 69.7 77.6 68.0 75.9 70.6 75.2 -       65.0 65.4 63.9 60.5
15-44 years 91.8 92.1 91.3 92.6 86.0 94.0 90.0 93.3 92.0 92.5 -       93.0 93.0 97.3 90.0
45-54 years 91.9 93.7 88.9 90.4 95.4 91.8 82.1 89.7 91.9 88.5 -       83.8 83.9 87.2 80.5
55-64 years 86.7 87.5 85.6 84.9 83.0 88.2 79.1 84.7 80.6 89.8 -       79.1 79.8 71.3 73.9
65-74 years 77.9 77.5 78.3 79.3 69.0 83.8 72.9 80.0 72.4 80.1 -       65.9 66.1 64.3 62.9
75-99 years 46.6 44.9 49.1 52.8 45.4 53.1 43.1 54.8 46.7 49.0 -       38.5 38.9 39.9 32.2
Five years Age-standardised 37.5 39.9 34.2 41.9 36.9 44.1 28.8 43.2 36.1 39.7 -       36.4 36.4 36.5 36.3
15-44 years 69.8 72.8 66.1 75.8 65.6 74.4 72.1 77.8 72.9 76.1 -       79.4 79.1 86.3 80.2
45-54 years 58.2 62.1 52.5 60.7 64.6 62.6 47.2 60.5 56.0 56.9 -       54.0 53.8 53.1 57.1
55-64 years 41.8 42.1 41.1 47.3 42.0 47.8 31.1 49.3 40.4 46.9 -       42.2 42.2 34.3 45.5
65-74 years 38.6 41.1 35.2 38.9 32.7 43.3 28.6 39.6 34.5 38.4 -       32.4 32.5 34.1 29.8
75-99 years 16.6 19.8 12.3 24.7 18.7 26.8 9.2 26.6 17.1 19.4 -       18.0 18.0 21.7 16.4
No. of patients 2,303 1,312 991 5,466 563 915 274 3,714 1,720 1,467 -       16,350 14,825 532 993
Age-standardised 48.7 52.7 43.5 54.4 50.8 55.8 39.1 55.7 48.8 50.9 -       53.8 53.5 55.7 57.4
15-44 years 76.0 79.1 72.3 81.9 76.3 79.2 80.1 83.4 79.3 82.2 -       85.4 85.0 88.7 89.1
45-54 years 63.4 66.3 59.0 67.1 67.7 68.3 57.4 67.5 61.0 64.3 -       64.4 64.1 60.9 71.0
55-64 years 48.1 48.1 48.0 55.6 50.7 54.2 39.3 58.2 50.1 52.2 -       53.3 53.0 48.2 61.6
65-74 years 49.6 53.0 45.0 49.0 47.3 51.7 39.3 49.5 47.6 48.0 -       49.2 49.2 53.0 47.4
75-99 years 35.7 44.1 25.1 46.8 41.2 50.5 21.3 48.6 36.6 39.7 -       46.7 46.3 54.3 51.0
Some age-standardised estimates arise from imputed age-specific estimates (see text)
Patients included in conditional five-year survival estimates are those who survived at least one year after diagnosis (see text)
Patients included in the period analysis are those who were diagnosed during 2005-07, or diagnosed earlier but alive on 1 January 2005 (see text and Figure 1 in The Lancet article)
Conditional 5-year
Conditional 5-year
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Colorectum Breast Ovary
Persons Males Females Persons Females
Incidence*
Australia 40.3 38.2 17.5 27.0 84.4 8.0
Canada
1
35.6 47.9 31.6 38.9 80.7 9.4
Denmark 33.9 46.2 31.6 37.9 83.7 13.2
Norway 36.1 35.5 19.2 26.4 71.0 12.8
Sweden 26.3 20.9 14.5 17.3 78.9 10.5
UK
2
29.3 43.8 22.6 31.9 82.1 11.9
Mortality
Australia 14.2 32.1 13.6 22.1 16.6 4.8
Canada 12.2 44.5 24.8 33.5 18.3 5.4
Denmark 17.8 42.6 27.6 34.1 25.2 8.7
Norway 16.0 31.2 15.3 22.4 16.8 7.1
Sweden 11.5 21.0 13.4 16.7 15.8 6.7
UK
3
12.7 39.5 19.9 28.4 21.5 7.7
Mortality/Incidence ratios
Australia 0.35 0.84 0.78 0.82 0.20 0.60
Canada
1
0.34 0.93 0.78 0.86 0.23 0.57
Denmark 0.53 0.92 0.87 0.90 0.30 0.66
Norway 0.44 0.88 0.80 0.85 0.24 0.55
Sweden 0.44 1.00 0.92 0.97 0.20 0.64
UK 0.43 0.90 0.88 0.89 0.26 0.65
Source for incidence rates around 2000 (1998-2002): Cancer Incidence in Five Continents, vol IX
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England and Northern Ireland only; 
3
 England and Wales only
Table 15: Age-standardised (world) annual incidence and mortality rates per 100,000 in 2000, 
with mortality-incidence ratios: cancer and country
Lung
* Colorectal cancer includes cancers of the anus and anal canal; lung cancer includes cancers of the 
trachea.










































































































































































































































1985 1990 1995 2000 2005
Year of death
Lung: Women
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